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Abstract 
 
eBusiness is rapidly becoming the defacto business model of many firms.  
The pharmaceutical industry will continue to thrive regardless of recession, 
terrorism, war, or other external forces.  Question is:  what eBusiness 
technologies and trends are being currently pursued by pharmaceutical 
companies in managing critical relationships with business partners such as 
doctors, physicians, suppliers, retailers, distributors, and consumers?  The 
purpose of this research is to provide a high-level overview of the 
pharmaceutical industry and companies that dominate in this vast arena.  
This is followed by an in-depth analysis of eBusiness in terms of phases, 
models, architectures, vendors, and products.  Finally, eBusiness 
technologies and trends in global pharmaceutical organizations related to 
procurement, sales, and supply chain are analyzed in various case studies.  
This analysis ultimately leads to a carefully orchestrated conclusion that 
recaps this entire research based on eBusiness in the pharmaceutical industry. 
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Introduction 
Gartner predicts that IT spending in the pharmaceutical industry will increase 
from $3 billion in 2000 to $5 billion in year 2005.  IT spending is categorized into 
hardware, software, and networks.  The software component is composed of various 
categories, one of which is eBusiness, a term coined by IBM in 1997.  
Kalakota refers to eBusiness as the 3rd phase (beyond 2000) of e-commerce, 
where the main goal of organizations is to focus on how the Internet can increase gross 
margins.  Kalakota goes on to define eBusiness as not just about e-commerce 
transactions or about buying and selling on the Webits the overall strategy of 
redefining old businesses which, with the aid of technology, maximize customer value 
and profits.1 
This thesis facilitates a discussion about existing eBusiness technologies and 
trends within the pharmaceutical industry.  How are pharmaceutical companies selling 
their products using the Internet?  What eBusiness solutions have been implemented to 
manage supply chains and procurement activities?  What technologies, if any, did these 
pharmaceutical companies use in the past to sell products or manage the supply chain, 
versus what technologies are being currently used in eBusiness implementations?  It is 
fascinating to see that companies still have ecommerce links on their corporate website 
where business partners have the option to upload the obsolete, yet proven, Electronic 
Data Interchange (EDI) files to order products.   
Additionally, what eBusiness models are being pursued?  What emerging 
eBusiness technologies can impact pharmaceutical companies in the near future?  What 
                                                
1 Ravi Kalakota and Marcia Robinson, e-Business 2.0: Roadmap for Success, Addison-Wesley, Boston, 
2001, p. 5. 
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challenges and issues did they face with their eBusiness solutions?  Are package 
solutions more useful than custom eBusiness solutions?  What eBusiness products and 
vendors were utilized in organizations?  How is Pfizer selling Viagra® to its business 
partners such as doctors who can then prescribe this product to their patients?  Is it via 
salespeople, or phone and fax orders, or through online transactions?  Furthermore, how 
is Johnson & Johnson selling Tylenol® to business partners and consumers?  These 
questions just scratch the surface of this research that tries to delve deep into the 
pharmaceutical industry to see how eBusiness is being performed in this relatively low-
key industry when compared to other high-tech industries such as financial services. 
Thesis Layout 
This thesis initially provides a high-level overview of the pharmaceutical industry.  
This is followed by a discussion of the leading players in the pharmaceutical industry.  
Next, eBusiness is discussed in terms of phases, models, architectures, vendors, products, 
and how they are applicable in the pharmaceutical industry.  Furthermore, this thesis 
delivers a variety of case studies of eBusiness implementations in various pharmaceutical 
organizations, specifically related to procurement, sales, and supply chain management.  
Finally, a conclusion is derived that allows us to see existing eBusiness technologies and 
trends in the aforementioned phases of the pharmaceutical companies, and where this 
industry is heading in the near future.   
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1.0. Chapter One: The Pharmaceutical industry 
The Pharmaceutical Research and Manufacturers of America (PhRMA) states in 
their 2002 annual report that pharmaceutical companies will advance the frontiers of 
medical science by continuing to develop new life-saving, cost-effective medicines, 
vaccines, and other therapies to predict, prevent, diagnose, treat, and cure disease.2  The 
pharmaceutical industry is focused on the well-being of humans and animals.  This goal 
is being achieved by performing extensive research to develop drugs, medications, and 
vaccines to treat diseases that incur high tolls in terms of human lives and financial costs.  
Pharmaceutical firms will spend in excess of $30 billion in the US alone in 2003 to 
research and develop new drugs and medications.3  The pharmaceutical industry has 
delivered many products that treat conditions like cancer, vision correction, impotence, 
gastrointestinal disorders, AIDS, HIV, colds, flu, diabetes, hypertension, hyperactivity, 
depression, and many more diseases that affect millions of lives throughout the world.   
The goal of this research is to determine the role of the Internet and Information 
Technology (IT) in the pharmaceutical industry for selling drugs and medications to 
business partners such as doctors, physicians, wholesalers, distributors, and retailers.  
This research will analyze how pharmaceutical firms implement eBusiness solutions for 
their business partners in both front-end (customer interface) and backend business 
processing.  There are four eBusiness models being pursued in the pharmaceutical 
industry.  First of all, there are the content providers such as WebMD and MedScape, 
who provide online data related to health, drugs, and diseases.  Secondly, there are 
                                                
2 Pharmaceutical Research and Manufacturers of America, Annual Report 2001-2002: New Medicines New 
Hopes, www.phRMA.org. 
3 Ibid 
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market-makers, such as HealthAxis or Neoforma, who are application services providers 
to pharmaceutical companies for establishing a web presence and performing online 
business.  Thirdly, there are eTailers such as drugstore.com or cvs.com who provide the 
Business-to-Consumer (B2C) interface for many pharmaceutical companies.  Finally, 
there are service providers such as InfoMedics who provide products and services to 
pharmaceutical companies, in regards to detailing, gaining market share, and increasing 
brand performance.  This research is interested in eBusiness models where products are 
being sold to business partners and consumers. 
1.1. Pharmaceuticals Value Chain 
McAfee mentions that the Internet will strongly influence strategies of 
pharmaceutical companies.4  The following steps portray a typical pharmaceutical drug 
manufacturing process:    
 
Figure 1-1  Pharmaceutical Value Chain5 
 
McAfee further notes that data-sharing, databases, connectivity, and quick 
screening will influence the Research phase.  Similarly, recruiting, data capture, and 
virtual trials will impact Preclinical and Clinical Development.  Branding, product data, 
                                                
4 Andrew McAfee, eBusiness at Novartis, Harvard Business School, August 2001. 
5 Ibid 
 
Research 
 
Pre-Clinical  
Development
 
Clinical 
Development
Marketing
 
Sales 
 
Supply Chain
Management 
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and online communities will affect Marketing.  Furthermore, online sales and detailing 
will influence the pharmaceutical firms Sales.  Finally, forecasting, procurement, and 
place & trace order will influence supply chain management (SCM) in this industry.  The 
main interest of this research will be on the impact of the Internet on eBusiness, therefore, 
mainly related to the Sales and SCM processes in the pharmaceutical industry.   
1.2. Key Processes 
The pharmaceutical industry is highly regulated and several key processes make 
this an extremely competitive market.  Key processes in developing drugs in the 
pharmaceutical industry include drug discovery, drug development, and clinical trials.  
Additional processes for distributing drugs to partners such as pharmacies, doctors, and 
wholesalers include sales, marketing, and SCM.  The Internet and IT play critical roles in 
all these processes. 
1.2.1. Food and Drug Administration 
 
The primary responsibility of Food and Drug Administration (FDA) is protecting 
public health by permitting safe and effective products to reach the market in a timely 
manner and monitoring products for continued safety after they are in use.6  The FDA is 
the governing body in the pharmaceutical industry and is responsible for setting standards.  
Historically (since colonial times), individuals and companies in the US have claimed to 
have developed the all-curing drugs.  However, it was not until the 1930s when the 
Federal Food, Drug, and Cosmetic Act (FD&C) was enacted to set standards for 
approving new drugs.  Besides, it was not until the 1960s that standards for drug efficacy 
                                                
6 Lambert van der Walde and Kristen Choi, Health Care Industry Market Update: Pharmaceuticals, 
Centers for Medicare and Medicaid Services, January 10, 2003, p.14. 
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and safety were brought forth.  Since then, the FDA is the leading federal agency to 
monitor prescription drugs sold to patients and has the authority to withdraw any drug 
from the marketplace if public health risk becomes high and they overshadow the 
benefits. 
1.2.2. Drug Discovery 
 
 Drug discovery is associated with identifying drug targets that could add value to 
society by curing diseases.  The primary goal of the drug discovery process is to find 
multiple factors that are causing the disease.  The role of IT in this phase is associated 
with data-sharing, databases, and connectivity.  It is critical for pharmaceutical 
companies to maintain, exploit, and exchange data related to drug discovery.  Hence, 
drug discovery precedes pre-clinical testing and is concerned with identifying targets.   
1.2.3. Drug Development 
 
Drug development includes pre-clinical testing.  This is performed by scientists in 
pharmaceuticals labs to test new compounds.  These compounds are believed to provide 
benefits such as prevention, cure, or treatment of a medical condition.  Screenings in the 
drug development phase could be performed on between 5,000 to 10,000 drug candidates, 
and 250 of those make it to the final pre-clinical trails.7  Drug development sets the 
precedence for the clinical trials. 
Clinical trials in drug discovery are critical to delivering a valuable drug in the 
pharmaceutical industry.  These three-part stages are described in the Table 1-1.  Seldom, 
                                                
7 Ethan Parvis, The Pharmaceutical industry: Access and Outlook, Nova Science Publishers, Inc., New 
York, 2002, pp.87-100.  
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a Phase IV may be required for additional testing.  Typically, 2 of 20 drugs tested survive 
all three phases. 
Phase # of Humans Approximate Cost Duration 
Phase I 100  150 $10 million 1  2 Years 
Phase II 50  500 $20 million 2 - 3 Years 
Phase III 1000+ $30 million 3  5 Years 
Table 1-1  Drug Discovery Phases8 
 
The role of IT in both preclinical and clinical development is equally important.  
IT is used for recruiting, data capture, and virtual trials.  The Internet can serve as a 
powerful median in recruiting candidates for drug testing versus more primitive 
mechanisms such phone calls, conferences, or seminars.  Similarly, using the Internet to 
capture candidate or patient data allows for faster and more efficient process in selecting 
the drugs candidate pools.  Finally, virtual trials can be held over the Internet is order to 
ease the process and duration.  In summary, IT and the Internet offer a variety of 
opportunities in the clinical phases of drug development. 
The three phases in clinical trials are typically followed by the New Drug 
Application (NDA).  The NDA is filed to the FDA while seeking approval to market the 
drug to consumers.  This stage may take several months to several years.  The duration is 
determined by the complexity of the drug and size of the NDA.  Thus, we see that all 
three phases in clinical trails are time-consuming, expensive, require hundreds of drug 
candidates, and dependent on IT. 
1.2.4. Marketing 
 
                                                
8 Ibid. 
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Marketing is critical to the success of drug development.  This phase consists of a 
process called Detailing in which pharmaceutical companies establish and build 
relationships with physicians and other vendors in the pharmaceutical value chain for 
delivering the drug to consumers.  According to Allison, eBusiness Strategy Director at 
one of the top 10 pharmaceutical company in the world, you cannot eDetail all your 
products,9 because this can be extremely expensive and not a feasible option in terms of 
cost and time.  Commonly, firms may spend the same amount on developing a drug as 
compared to marketing it.  Detailing is practiced via doctor office visits, seminars, and 
conferences.  IT is critical in this phase because items such as branding, product data, and 
online communities are created in this phase.  Firms can establish websites where 
information for doctors and potential patients is readily available for review.  
Additionally, online communities can be created where forums related to drug 
information and related feedback can be shared freely.   
The final phase of place / trace an order and SCM of the drug development 
process is related to eBusiness.  This phase will be part of the focus of this research.  
Companies have developed both front-end and backend eBusiness infrastructures to sell 
their drugs to business partners, consumers, wholesalers, distributors, to effectively use 
the Internet and IT in completing their value chain.  While custom software solutions 
have been developed, eBusiness package solutions have also been implemented to sell 
products over the Internet.  Many trends and technologies have emerged in this phase of 
delivering products to the customers and that will be the focal point of this thesis.   
                                                
9 Interview: Allison. 
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1.3. Key Factors 
Several key factors strongly influence the pharmaceutical industry.  This includes 
prescription drugs, health insurance, online pharmacies, generic drugs, and the health 
care market.  These factors collectively determine how eBusiness is conducted in the 
pharmaceutical industry.  
1.3.1. Prescription Drugs 
 
 Average drug industry profit margins range from 16% - 24 %...( and) in 2001 
prescription drug spending in the US totaled $141 billion, or 10% of national health 
expenditures, (of which) they are the fastest-growing segment.10  As these statistics 
prove, developing the right prescription drug is worth the cost and effort because the 
return on investment (ROI) is extremely high in the pharmaceutical industry.  In terms of 
pricing, uninsured consumers are paying relatively higher amounts than insured 
consumers for prescription drugs.  Medicare is an alternative for alleviating healthcare 
costs, however, it does not typically apply to prescription drugs.  PhRMA believes that a 
reformed Medicare would use the power of the marketplace to foster competition among 
private plans, resulting in more choices of high quality for Medicare beneficiariesthe 
right reforms would expand prescription drug access for all, provide special assistance to 
those in need, and deliver high quality care.11  The cost of prescription drugs is of 
concern to the US Congress and is being debated on many fronts.   
                                                
10 Lambert van der Walde and Kristen Choi, Health Care Industry Market Update: Pharmaceuticals, 
Centers for Medicare and Medicaid Services, January 10, 2003, pp. 5-8.  
11 Pharmaceutical Research and Manufacturers of America, Annual Report 2001-2002: New Medicines 
New Hopes, p.11, www.phRMA.org 
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Uninsured consumers are extremely price sensitive and they create a highly 
inelastic demand.  On the contrary, industry consumers and insurers are price insensitive 
and they create a highly elastic demand for prescription drugs.  Uninsured patients often 
pay full price for the products and this cost gets even higher for the elderly whose 
medication and prescription may be higher in quantity and cost, whereas the insured 
patients often pay a co-payment for buying their prescription drugs.  It is evident that the 
cost of prescription drugs developed by pharmaceutical companies impacts the market 
conditions and the overall pricing. 
 Custom software eBusiness solutions are effective when ordering drugs and 
medications that require extensive prescription data.  Products such as a prescription 
contact lens, for example, are associated with extensive parametric data such as base 
curves, prescription strength, color, brand, and type, which can only be delivered by 
creating a custom user interface for the business partners in ordering that product.  
eBusiness sales, ordering, and checkout scenarios can be implemented using software 
that allows users to place complicated orders over the Internet.   
1.3.2. Pharmacies 
 
 Pharmacies, such as CVS, Walgreens, or Eckerd, purchase and sell 
pharmaceuticals drugs.  To the concern of consumers and lawmakers, pharmaceutical 
firms may be performing price discrimination, because they do not sell directly to 
consumers, and possibly charge different prices to wholesalers and distributors.  Research 
shows that pharmaceutical companies can have so-called launch prices of their products; 
however, they cannot exercise a monopolistic status in this case.   For instance, in case of 
Glakso-Smith-Kline developing the ulcer treatment product, Zantac®, they are competing 
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with existing over-the-counter (OTC) versions of Pepcid AC® developed by Johnson & 
Johnson and Merck.12  It is clear that pharmaceutical firms can control the price used by 
the pharmacies to sell products they have developed. 
1.3.3. Online Pharmacies 
 
Online pharmacies have made a major impact on eBusiness in the pharmaceutical 
industry.  Both cvs.com and drugstore.com are actively involved in partnerships with 
pharmaceutical companies in selling their products online.  Tylenol, by Johnson & 
Johnson, is available at both these online pharmacies.  Exhibit 1-1 displays a snapshot of 
the cvs.com online pharmacy.  This website allows users to compare drug prices, fill 
prescriptions, setup reminders for placing refill orders, and read drug-related literature.  
Exhibit 1-2 displays the online pharmacy, drugstore.com.  This website allows 
consumers to view data about drugs, seek online advice from pharmacists, check order 
status, and place order for refills.  In review, the emergence of online pharmacies is 
impacting eBusiness in the pharmaceutical industry. 
A major issue with online pharmacies is that many consumers are bypassing 
traditional handwritten pharmacies and placing orders for drugs from websites being 
operated in other countries where rules are less strict and prices are comparatively much 
cheaper.  CanadaPharmacy.com, for example, bases its marketing strategy around the fact 
that they are more than 700,000 customers strong and they ship to the USA.13  Exhibit 1-
3 displays a screen shot of CanadaPharmacy.com.  Additionally, MyMeds.org, displayed 
in Exhibit 1-4, offers to sell prescription drugs from Mexico and Canada to consumers 
                                                
12 Ethan Parvis, The Pharmaceutical industry: Access and Outlook, Nova Science Publishers, Inc., New 
York, 2002, p. 37. 
13 www.CanadaPharmacy.com, March 2003. 
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for less than 80% of price paid in the US.14  Online pharmacies operating in neighboring 
Canada and Mexico offer substantially lower prices for prescription drugs and definitely 
impact eBusiness in the pharmaceutical industry.  
1.3.4. Drug Pricing 
 
Drug pricing is relatively high in the US when compared to its neighbors.  This 
may be the reason for aforementioned firms such as CanadaPharmacy.com or 
MyMeds.org to thrive in the online pharmaceuticals business.  In a survey of prices of 
121 drug products, only 22 were cheaper in the US.  The remaining 99 products were at 
least 10% more expensive than Canada.  In 21 cases, these products were more than 
100% expensive, while in 8 cases, more than 200% more expensive.15  One reason for 
cheaper drug prices in Canada and Mexico is the fact that the governments in these 
countries are the primary payers of drugs.   
1.3.5. Generic Drugs 
 
As generic drugs become more common, the branded pharmaceutical industry 
faces increasing pricing pressure(as) $30 billion (2001 US sales) of branded drugs are 
losing patent protection over the next four years.16  Generic drugs can deeply impact 
branded pharmaceutical drugs in the next few years, because they can be developed after 
the original drug patent expires.  Historically, the generic drugs market was only 2% in 
the 70s, due to fact that the government required manufacturers of generics to carry out 
the same tests as the original manufacturer, plus only special permission had to be given 
                                                
14 www.MyMeds.org, March 2003. 
15 Ethan Parvis, The Pharmaceutical industry: Access and Outlook, Nova Science Publishers, Inc., New 
York, 2002, p.46. 
16 Lambert van der Walde and Kristen Choi, Health Care Industry Market Update: Pharmaceuticals, 
Centers for Medicare and Medicaid Services, January 10, 2003, p.6.  
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by physician to prescribe this.  However, in the early 80s a new law was enacted that 
eventually led to buyers gaining power in buying prescription drugs.  Today, the quality 
of generic drugs is equally good.  The generic drug industry saw average revenue 
growth spike from 14% in 2000 to 55% in 2001.17  This growth was due to expirations 
of many patents on branded drugs. Additionally, it takes generic drugs six to eights weeks 
to take more than 50% of the market share from branded drugs (six months in the past).  
Thus, generic drugs are an important factor in the pharmaceutical industry.   
1.3.6. Research & Development 
 
Branded pharmaceuticals depend on innovate Research & Development (R&D) 
to produce new medical treatments that are key drivers for long-term growth, making 
R&D the most important expense item in the industry.18  High costs related to R&D 
strongly impact the pharmaceutical industry.  According to PhRMA, $30 billion were 
spent on research in 2001.  This amount was an increase of more than 16% from 2000.  
Of this, $24 billion were spent on R&D in the US alone.  Pharmaceutical R&D target 
areas are ordered in terms of priority and spending in the following list: nervous systems 
related diseases (depression, Alzheimer), cancer, diabetes, cardiovascular diseases, anti-
viral, antibiotics, and respiratory system related disease (asthma, tuberculosis).   
1.3.7. Healthcare Market 
 
The healthcare market has strong internal rivalries and the barriers to entry are 
quite high.  Most drugs are sold by the pharmaceutical firms to wholesalers who then sell 
them to pharmacies, mail order, hospitals, health maintenance organizations (HMOs), and 
                                                
17  Ibid. 
18  Ibid, p.13. 
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other health care organizations.  This eBusiness aspect of this research will look at 
partnerships in this sector and market segment.  The cost of discovering, developing, and 
manufacturing drugs is high and is encompassed by a rather risky and time-consuming 
process.  Statistics show that 1 in 83,000 to 167,000 (deliver) positive net returns on 
investment.19  It typically takes 12 years for a drug to evolve from an idea to a product for 
the consumer. 
 Finally, health expenditure is one of the key drivers that impact the 
pharmaceutical industry.  Health expenditures were nearly $1.4 trillion in the US in 2001.  
The Health Care Financing Administration (HCFA) mentions several components of the 
health care industry.  These components include:  health care (30%), physician service 
(22%), nursing homes (7%), and prescription drugs (8%).20  Various components make 
up the tremendous costs that are incurred in the health care industry. 
1.4. Conclusion 
 Pharmaceutical companies spend billions of dollars researching, developing, and 
manufacturing drugs for curing diseases in humans and animals.  After a birds eye view 
of the pharmaceutical industry, the following chapter will discuss who is who in this vast 
spectrum of pharmaceutical drug manufacturing companies.  This chapter contains a list 
of many dominant players in the pharmaceutical industry, a brief history, products they 
develop, and business information such as sales, profits, and number of employees.  
eBusiness initiatives at these companies will be mentioned as well.     
                                                
19 Ethan Parvis, The Pharmaceutical industry: Access and Outlook, Nova Science Publishers, Inc., New 
York, 2002, p. 133. 
20 Ibid. 
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1.5. Exhibits 
 
Exhibit 1-1  CVS Online Pharmacy Store 
 
Exhibit 1-2  DrugStore.com 
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Exhibit 1-3  CanadaPharmacy.com 
 
Exhibit 1-4  MyMeds.org  
   24
2.0 Chapter Two:  Who is Who in Pharmaceuticals 
There are many players in the vast arena of pharmaceutical companies.  This 
chapter provides a high-level overview of this industry before we begin a discussion 
about eBusiness trends within this playing field.  Many consumer products and drugs we 
use in our daily lives are developed by pharmaceutical firms that have been around for 
decades.  These companies spend billions of dollars annually while researching new 
drugs for providing treatment for diseases suffered by millions of humans and animals. 
Table 2-1 provides a selective list of companies in the pharmaceutical industry 
and offers useful data such as company size, famous brands, sales / profits figures, and 
the firms competitive advantage.  This list includes the top 10 manufacturers in the US 
by prescription sales.21 
  
Company Famous Brands and Affiliates Sales /  
Profits /  
Employees 
(2001) 
Competitive 
Advantage 
Abbott 
Laboratories 
(ABT) 
! Biaxin® - Respiratory Illnesses 
! Depakote® - Epilepsy  
! Erythromycin® -  Antibiotics 
! Norvir® - HIV / AIDS 
! Prevacid® - Gastrointestinal 
! Survanta® - Respiratory Diseases 
! Similac®, Pedialyte® 
! Tricor® -  Cardiovascular Illnesses 
$16 Billion /  
$1.5 Billion / 
70,000+ 
Heavy research, 
worldwide 
recognition, and 
leading producer of 
antibiotics. 
AstraZeneca 
(AZN) 
! Accolate®, Faslodex® 
! Atacand® - Hypertension 
! Diprivan®, 
! Nexium® -  Gastrointestinal 
! Prilosec® 
! Pulmicort Respules® 
! Seroquel® - Schizophrenia 
! Zomig® - Migraine 
$16.5 Billion /  
$1.1 Billion /  
54,000+ 
One of top 5 leading 
R&D-based 
pharmaceutical 
company with 
revenues from more 
than 100 countries.  
Focus on 
cardiovascular, 
cancer, nervous 
                                                
21 Lambert van der Walde and Kristen Choi, Health Care Industry Market Update: Pharmaceuticals, 
Centers for Medicare and Medicaid Services, January 10, 2003, p.9. 
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system, and pain 
management.  
Bayer 
(BAY) 
! Avelox® - Skin Infections 
! Bayer Aspirin 
! Cipro® - Antibiotics 
! Levitra - Erectile Dysfunction 
(GSK) 
! Precose® - Type 2 Diabetes  
! Viadur® - Prostate Cancer Treatment 
$30 Billion /  
$965 Million / 
140,000+ 
International 
research-based firm 
that focuses on life 
sciences, polymers, 
chemicals, and 
pharmaceuticals.  
Bristol-
Myers 
Squibb 
(BMY) 
! Avapro® - Hypertension 
! Clairol® 
! DuPont Pharmaceuticals  
! Glucophage® - Type 2 Diabetes 
! Excedrin® - Migraine (1st OTC) 
! Nice nEasy® 
! Plavix® - Anti-Platelet 
! Pravachol® Cardiovascular Diseases  
! Taxol® - Cancer injections 
! Videx® - HIV  
$19.4 Billion /  
$5.2 Billion / 
46,000 
One of the largest 
personal care and 
health companies in 
the world.  Develop 
pharmaceutical 
products, over-the-
counter medication, 
beauty aids, and 
nutritional products.  
Pharmaceuticals 
focus on cancer, 
diabetes, HIV/AIDS, 
and pain. 
Eli Lilly 
(LLY) 
! Gemzar® - Lung Cancer  
! Humalog - Diabetes (Insulin) 
! Prozac® - Depression  
! Singapore Economic Development 
Board 
! Strattera - Attention-Deficit / 
Hyperactivity Disorder in Children 
$11 Billion / 
$2.8 Billion / 
40,000+ 
Pharmaceuticals 
products are world 
famous.  Products 
line treats ulcers, 
infections, and 
cardiovascular 
diseases. 
Glakso-
Smith-Kline 
(GSK) 
! Amoxil - Respiratory Infections 
! AquaFresh - Oral Healthcare 
! Avandia - Type 2 Diabetes 
! Citrucel - Gastrointestinal 
Disorder  
! Tums - Gastrointestinal Disorder 
! Glaxo Wellcome® 
! Horlicks and Ribena - 
Nutritional Healthcare 
! Lanoxin - Chronic Cardiac Failure 
! Macleans - Oral Healthcare 
! Neosporin - Eye Infections  
! Polyfax - Eye Infections 
! Nicorette - Nicotine Replacement  
! Oxy - Skin Care 
! SmithKline Beecham® 
! Tagamet / Zantac / Rantidine 
- Ulcer and Gastrointestinal Disorder 
! Zantac® 
$30 Billion /   
-$160,000 / 
100,000+ 
World leading 
healthcare firm.  One 
of the largest health 
care firms in UK.  
Pharmaceutical drugs 
treat epilepsy, ulcers, 
heart diseases, 
infections, and 
depression. 
Hoffman 
La-Roche 
! Furtulon - Colon Cancer 
! Fuzeon - HIV 
$21 Billion / 
$2.3 Billion / 
Established 
developers of drugs, 
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! Herceptin - Breast Cancer  
! Pegasis - Hepatitis C  
! Rapilysin - Heart Attack 
! Roaccutan - Skin Care  
! Xenical - Obesity,  
70,000+ pharmaceuticals, and 
vitamins that are used 
worldwide. 
Johnson & 
Johnson 
(JNJ) 
! Acuvue® - Vision Correction 
! ALZA Corporation 
! Baby Center 
! Band-Aid® - Minor Cuts 
! Cypher® - Stents 
! Heartport 
! Janssen 
! Mylanta®, AcipHex® - Indigestion 
! Neutrogena® - Skin and Hair Care 
! ORTHO  Orthopedic Products 
! Pepcid® - Heartburn Treatment 
(Merck) 
! Prevacare® 
! Reach® - Oral Healthcare 
! Tylenol®, Motrin® - Pain Relief 
$33 Billion / 
$5.7 Billion / 
101,000+ 
Largest manufacturer 
of health care 
products in the world.  
Delivered to 
consumers, 
pharmaceuticals, and 
professionals in the 
health care industry. 
Merck 
(MRK) 
! Hyzaar® - High Blood Pressure  
! Merck-Medco Managed Care 
! Propecia® - Male-pattern Baldness 
! Singulair® - Asthma 
! Stocrin® - HIV   
! Vioxx® - Arthritis 
! Zocor® - High Cholesterol 
$48 Billion /  
$7 Billion / 
78,000+ 
Delivers world class 
drugs and owns 
enormous research 
facilities. 
Novartis 
(NVS) 
! CIBA-Geigy 
! CIBA® Vision - Vision Correction 
! Diovan® - Hypertension 
! Ex-Lax® - Laxative 
! Gerber® - Baby Formula 
! Gleevec - Leukemia 
! Grand Laboratories 
! ImmTech Biologics 
! Lamisil® - Anti-Fungal 
! Maalox® - Antacid 
! Theraflu® - Cold and Flu 
! Triaminic® - Cold and Flu 
$19 Billion / 
$4.1 Billion / 
68,000+ 
One of the leading 
pharmaceutical 
companies of the 
future that has 
created a strong 
foundation via 
acquisitions and 
research.  Products 
for humans, animals, 
and crops.   
Pfizer 
(PFE) 
! Accupril®, Celebrex® - Arthritis 
! Actifed® - Cold and Sinus  
! Benadryl® - Cold and Sinus 
! BENGAY® - First Aid  
! Cortizone® - First Aid 
! Dentyne®, Bubblicious®, Trident® - 
Gum and Throat Drops 
! Halls® - Cough 
! Lipitor® - High Cholesterol 
! Listerine® and Plax® - Oral Care 
! Lubriderm® - Skin Care  
$32 Billion / 
$7.8 Billion / 
90,000+ 
Products are sold in 
more than 150 
countries and 
acquisition of 
Pharmacia is 
considered a plus. 
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! Pharmacia 
! Rolaids® and Zantac® - Indigestion 
! Schick® - Shaving 
! Viagra® - Erectile Dysfunction 
! Viracept® 
! Visine® - Eye Care  
! Zyrtec® - Allergies 
Wyeth 
(WYE) 
! Advil® - Pain Relief 
! Allesse® - Birth Control 
! American Home Products 
! Centrum® - Vitamins Supplement 
! Effexor® XR  Depression 
! FluShield® - Flu Vaccine 
! Fort Dodge 
! Phenegran® - Motion Sickness 
! Premanin® 
! Robitussin® - Cold and Flu 
! Sonata® - Sleep Therapy 
! Zosyn® - Antibiotic 
$14 Billion / 
$2.2 Billion / 
52,000+ 
One of worlds 
leaders in 
manufacturing health 
care products.  
Provider of human 
and animal disease 
treatment products.  
Many over-the-
counter medication 
and prescription drug 
products. 
Table 2-1 - Health Care Industry Leaders22 
 
2.1. Pharmaceutical Companies 
 
The information provided in Table 2-1 reveals relationships between some very 
well known products and famous pharmaceutical companies.  Additionally, the business 
data such as sales, profits, and company size allows one to see the sheer strength of these 
firms in terms of the products they sell to their business partners.  This research will soon 
discuss how eBusiness is helping these firms sell their products. 
A brief history, products, research areas, divisions, and eBusiness initiatives of 
the companies mentioned in Table 2-1 is necessary.  The intent here is not to provide 
detailed information for all the players in the pharmaceutical industry, rather an attempt 
to provide the reader a flavor of the broad spectrum of who is who in this vast spectrum 
                                                
22 Jack W. Plunkett, Plunketts Health Care Industry Almanac, 2003, Plunkett Research Ltd, Houston, 
Texas. 
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of companies.  Details include public information about these pharmaceutical companies 
that is related to a brief history, business segments, and eBusiness initiatives.   
2.1.1 Abbott Laboratories 
Abbott Laboratories was founded in 1888 by Dr. Wallace Abbot, while producing 
small pellets in his Chicago, Illinois apartment.  Within 40 years, this companys stock 
was trading on the Chicago Stock Exchange and through global and domestic 
acquisitions, joint-ventures, research-affiliations, and spin-offs over the subsequent 
decades, Abbott has become one of the worlds leading pharmaceutical firms.  Today, the 
company is headquartered in suburban Chicago, is represented in over 130 countries, and 
owns 130 real assets in manufacturing, distribution, and research and development.  
Abbott divisions include pharmaceuticals, nutritional, hospital products, diagnostics, and 
specialty.  Abbott Laboratories pharmaceuticals research has focused on antibiotics, 
treatment of migrations, epilepsy, HIV, AIDS, and manic depression.  
e-Abbott.com is Abbotts online initiative for selling products to their business 
partners.  Abbot Quick Link is a free multi-vendor ordering system that allows business 
partners to submit electronic purchase orders and retrieve confirmation from more than 
100 vendors.  Exhibit 2-1 shows the login screen for this online service.  Based on 
information provided at Abbotts corporate website, Quick Link is using the EDI 
technology to exchange data.  EDI is a form of electronic messaging and it allows 
companies to send / receive business documents (such as purchase orders) in a 
standardized form to / from suppliers.23  Abbot claims that their systems will integrate 
                                                
23 Ravi Kalakota and Andrew Whinston, Electronic Commerce, A Managers Guide, Addison-Wesley 
Longman, Inc., 1997, p.6. 
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with most software packages that are EDI-enabled.  This online service allows Business-
to-Business (B2B) ordering and status-checking capabilities.     
2.1.2. AstraZeneca 
AstraZeneca is one of the worlds top five leading researchers and manufacturer 
of prescription pharmaceutical products.  AstraZeneca corporate headquarter is located in 
the UK and their R&D headquarter is in Sweden.  This company has established a strong 
presence in the US.  AstraZeneca also owns an $8 billion healthcare business in the US 
that consists of more than 10,000 employees.  AstraZeneca focus is in the development of 
gastrointestinal, oncology, anesthesia, cardiovascular, nervous system, and respiratory 
products that are developed and used globally.  These products are prescribed worldwide 
in more than 100 countries, of which 20 countries contain manufacturing plants, and 
R&D centers in another 5 countries.   
According to a press release in AstraZeneca has both B2B and B2C models for 
eBusiness.  They have established a Global eBusiness team that is involved with targeting 
new customers and improving marketing of AstraZeneca brands on the Internet.  In terms 
of B2B initiatives, AstraZeneca is exploring opportunities to streamline business 
processes and drive growth through new channels to existing and new customers. 24  
Hence, AstraZeneca is shifting to the Internet to improve eBusiness relationships with 
business partners. 
                                                
24 AstraZeneca, Press Release: AstraZeneca announces appointment of Global E-Business Vice 
President, July 31, 2000, 
www.astrazeneca.com/mainnav1/mediaoffice/s_press/c_press/idc_press29817/press-release-086.html. 
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2.1.3. Bayer 
Widely known throughout the world for Bayer Aspirin, Bayer is more than just a 
firm delivering this tiny tablet.  Bayer US, headquartered in New Jersey, consists of the 
following four businesses:  healthcare, polymers, cropscience, and chemicals.  Healthcare 
consists of divisions in animal health, biologicals, consumer care, diagnostics, and 
pharmaceutical.  Bayer Pharmaceuticals in headquartered in Pittsburgh, PA and it is a 
wholly-owned subsidiary of Bayer AG, which in turn is a $30 billion company with 
nearly 140,000 employees working in almost 150 countries worldwide.  Bayer AG was 
founded in 1863 in Germany when its founder, Friedr Bayer began developing dyestuff.  
The pharmaceutical business of Bayer was established in 1881 and in 1899 a drug called 
Aspirin, which later became known as the drug of the century was developed.  Bayer 
Pharmaceuticals is involved with research and product development in the healthcare 
sector for prescription medication, biological products, biotechnology, and allergy-
prevention.   
Bayer has developed an extremely strong eBusiness infrastructure in their 
organization.  Their goal for 2004 is to sell nearly $5.5 billion worth of products on the 
Internet.  Several Bayer divisions are planning on generating half their sales revenue from 
the web.  Bayers online initiatives include eStrategy, eTransaction, eMarketplaces, and 
eProcurement.  eStrategy consists of eBusiness initiatives at Bayer that include electronic 
marketplaces and electronic transaction portals for B2B order processing.  Exhibit 2-2 is 
a snapshot of the eBusiness focus at Bayer.  In addition, Bayer offers business to 
consumer portals for customers to order their prescription medication.  Exhibit 2-3 is a 
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snapshot of this B2C portal.  Hence, Bayer seems to highly leverage the Internet to 
maintain relationship with consumers and business partners. 
2.1.4. Bristol-Myers Squibb 
Squibb was founded in New York in 1856 as a developer of pure medicines, 
while Bristol-Myers was founded in New York in 1887 as low-cost drug developer.  The 
two companies merged more than a hundred later in 1989 to create the second largest 
pharmaceutical enterprise in the world  Bristol-Myers Squibb.  More recently, in 2001, 
the company acquired DuPont Pharmaceuticals to further strengthen their business.  
Bristol-Myers Squibb owns a huge product portfolio that delivers treatment for diseases 
such as HIV, diabetes, hypertension, heart disease, and cancer.  
2.1.5. Eli Lilly 
Eli Lilly was founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana.  The 
founder, a chemist by trade and veteran of the US Civil War, established this research-
based firm after witnessing poor delivery of medical needs for patients in the Midwestern 
US.  Today, Lillys products a represented in nearly 160 countries.  Nearly 18% of Lillys 
employees are involved in research and development efforts.25  Lillys divisions are split 
amongst research laboratories for drug discovery, clinical research, and product 
development.  R&D therapeutic areas have been created at Lilly for curing urgent 
medical conditions such as diabetes, cancer, osteoporosis, and animal health. eLilly is 
Lillys subsidiary for implementing and managing eBusiness initiatives. 
                                                
25 www.lilly.com, March 2003.  
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2.1.6. GlaksoSmithKline 
GlaksoSmithKline (GSK), headquartered in the United Kingdom with major 
operations in the US, is a research-based pharmaceutical firm delivering products and 
drugs for therapeutic areas and consumer products.  About 70% of 2002 sales of 
pharmaceuticals at GSK came from new products, hence demonstrating a strong 
commitment of this firm to product innovation and research.  GSK owns operating units 
in 39 countries.  Sales and marketing concerns at GSK factor for nearly 40% of the firms 
employees and another 15% is involved with R&D efforts.  GSKs products are 
categorized in consumer healthcare, prescription medication, and vaccines.   
In 2001, the CIO of GSK was quoted as saying we have made no grand 
organization commitment to e-Healthwe have set up a small office to sense what the 
world is doing and to encapsulate those learnings and make sure we understand 
thembut at this stage we dont believe well gain those changes by bolting the Internet 
onto the company.26  Hence, GSKs strategy for embracing the Internet for any of the 
critical phases in drug development, marketing, or sales has been rather weak.  That is the 
reason no eBusiness links were available for professional.  Thus, firms such as GSK do 
exist out there with beliefs that the Internet and IT are not the cure all solution for their 
product development and delivery.   
2.1.7. Hoffman-LaRoche 
Hoffman-LaRoche was founded in 1896 by Fritz Hoffman-LaRoche in 
Switzerland with the primary goal to establish a firm that manufactures drugs at an 
industrial scale for fighting and curing diseases common at that time.  LaRoche has three 
                                                
26 Pharmaceutical Executive, What Chief Execs do know about the Internet, August 2000. 
   33
main operating divisions: pharmaceuticals, diagnostics, and vitamins & fine chemicals.  
LaRoche Pharmaceuticals employs nearly half the work force of Hoffman-LaRoche and 
contributed nearly 2/3rd of the annual sales at approximately $15 billion.  Nearly half of 
LaRoches employees are based in Europe.  LaRoche develops a variety of products for 
treatment of cancer, obesity, and HIV. 
LaRoche has a significant strategy for using the Internet for maintaining 
relationships with their customers.  Exhibit 2-4 shows the login screen for healthcare 
professionals.  This website allows business partners to view information about products 
delivered by LaRoche, in addition to placing orders online.  Exhibit 2-5 is LaRoches 
eBusiness and content website for Vitamins.  This website allows business partners, 
namely wholesalers and distributors, to perform online transactions such as ordering, 
tracking, creating catalogs, and requesting price quotes. 
2.1.8. Johnson & Johnson 
Johnson & Johnson was founded in the 1880s by Robert Wood Johnson and his 
brothers, who at that time were involved in providing antiseptic wound treatment in New 
Jersey.  For over 100 years, the company has been headquartered in New Brunswick, 
New Jersey.  Johnson & Johnson is known for its extremely decentralized structure and 
this firm has more than 200 operating companies in 54 countries.  Thousands of Johnson 
& Johnson products are sold in more than 175 countries.  Johnson & Johnson is 
composed of the following three main divisions: consumer, pharmaceuticals, and 
professional.27  Johnson & Johnson probably has one of the broadest product portfolio 
                                                
27 www.jnj.com, February 2003. 
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and recognizable name brands.  The firm produces products ranging from band-aids, 
contact lenses, pain relief tablets, shampoos, orthopedic products, and surgical devices.   
Johnson & Johnson has been known to be an innovator in the pharmaceutical 
industry and their global vision has enforced this fact by implementing executive vision 
of using the Internet to improve relationship with business partners.  JnJGATEWAY, 
shown in Exhibit 2-6 and Exhibit 2-7, is an example where business partners can order 
pharmaceuticals, surgical supplies, and other products from Johnson & Johnson.  The 
goal of JnJGATEWAY® is to provide a single point of contact as well as a single online 
face to their rather diverse and independent subsidiaries.  In addition, Johnson & Johnson 
has formed partnerships with pharmacies or wholesalers in selling their products online.  
Exhibit 2-8 shows a link to CVS and COSTCO for selling Johnson & Johnsons 
famous pain killer, Tylenol®.  Hence, Johnson & Johnson is using various effective 
strategies in using the Internet to perform eBusiness. 
2.1.9. Merck 
Merck is a world-renowned pharmaceutical firm that thrives based on research 
used to discover, develop, and manufacture products to cure diseases in humans and 
animals.  Merck is based out of Whitehouse station, New Jersey.  This firm has achieved 
a lot of success by developing products independently and also via joint-ventures and 
acquisitions.  The products at Merck can be separated into two categories: vaccines and 
medicine.  Most of the vaccines are related to treating worldwide diseases in adults and 
children and range from polio vaccinations to strep throat treatment.  Mercks products 
are geared towards treating serious diseases rather than developing consumer products.   
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In 2001, Merck launched their eBusiness initiative under the name, Merck-Medco.  
This subsidiary and its website allows Merck partners, namely physicians, clients, 
consumers, and pharmacists to access this website that was built using latest web-
enabling technologies.  The login for this website is shown in Exhibit 2-9.  Functionality 
includes placing and monitoring online orders, viewing drug information, maintaining 
prescription information, and additional health care information. 
2.1.10. Novartis 
Novartis was created in 1996 after one of the largest mergers in history between 
two Swiss firms, Sandoz and Ciba-Geigy.  Both Sandoz and Ciba-Geigy are known for 
developing chemicals and performing research in life sciences and their history dates 
back to the 1760s.  Novartis businesses are categorized in pharmaceuticals and consumer 
health.  The main business units consist of pharmaceuticals, generics, animal health, 
medical nutrition, infant and baby, and CIBA Vision.  Novartis products for consumer 
health and pharmaceuticals are known throughout the world.   
eBusiness at Novartis can be seen on their online B2B website for their vision 
care subsidiary, CIBA Vision®.  Exhibit 2-10 shows a snapshot of the eye care website 
where eye care physicians can place order for CIBA® contacts.  Functionality includes 
vision care product information along with order capabilities in three European countries.   
2.1.11. Pfizer 
Pfizer Inc., headquartered in New York City, New York, was founded in 1849 by 
Charles Pfizer & Company as a fine-chemicals business.  The company takes pride in its 
risk-taking strategy for developing new products, processes, and innovating to deliver 
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new products for humans and animals.  Pfizer is composed of the following three 
business units: health care, consumer health, and animal health.  Pfizer products include 
healthcare and consumer products.  These are worldwide brand names that are available 
in more than 150 countries.  Most consumer products can be differentiated between over-
the-counter and prescription drugs.  Pfizers recent acquisition of Pharmacia has made 
headlines and added to an already diverse portfolio of pharmaceutical drugs and 
consumer products.   
 Pfizer seems to be using obsolete yet proven technologies such as EDI for their 
eBusiness transactions.  Exhibit 2-11 and Exhibit 2-12 show Pfizer business units and 
EDI exchange capabilities with trading partners.  This includes the ability of groups with 
Pfizer pharmaceuticals to perform electronic transactions such as generating purchase 
orders, generating invoices, and cataloging products.  Additional usage of the Internet is 
prescribed by Pfizer to deliver account payable information to business partners as well 
as allowing vendors to perform business transactions with the IT group.  Pfizer is actively 
using the Internet to maintain B2B relationships and EDI is most commonly used. 
2.1.12. Wyeth 
Finally, Wyeth is another world-famous pharmaceutical company that uses 
significant research to discover, develop, and manufacture medicine for treating human 
diseases and is headquartered in Pennsylvania.  This company was founded as a drug 
store in Philadelphia, Pennsylvania in the 1860s by John Wyeth & Brother.  Wyeth is 
credited in history for developing the compressed pills (tablets) and gelatin capsules.  The 
four divisions at Wyeth include pharmaceuticals, research, consumer healthcare, and 
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animal health.  Wyeth develops a powerful range of OTC products and prescription 
medication sold in 140 countries, and they cure variety of diseases found in humans. 
2.2. Conclusion 
 
It is clear that the major players in the pharmaceutical industry have been around 
for many decades (some even centuries) and they have a strong reputation for delivering 
OTC and prescription drugs used throughout the world.  These companies employ tens of 
thousand of people worldwide and their sales are in the billions of dollars.  These large 
players in the pharmaceuticals generally have several different divisions and rely heavily 
on R&D to deliver new health care products. 
It is evident that eBusiness is heavily used by these prevailing companies in the 
pharmaceutical industry.  Using the Internet to perform electronics transactions with 
business partners, consumers, physicians, vendors, wholesalers, and distributors seems to 
be the norm in this industry.  Various models such as B2B, B2C, online partners, and 
gateways, are actively being pursued.  Older and reliable technologies such as EDI versus 
leading-edge technologies are offered throughout this spectrum of pharmaceutical 
companies discussed in this chapter.  
After discussing the dominant players in the pharmaceutical industry, this 
research transitions to eBusiness.  In the following chapter, we begin by defining 
eBusiness and the various models it encompasses.  Furthermore, we will discuss 
eBusiness phases and how they apply to the pharmaceutical industry.  
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2.3. Exhibits 
 
Exhibit 2-1  e-Abbott - Quick Link  
 
 
Exhibit 2-2  eBusiness at Bayer 
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Exhibit 2-3  Bayer Direct 
 
 
Exhibit 2-4  Roche Healthcare Professional Login 
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Exhibit 2-5  Roche eBusiness for B2B Ordering of Vitamins 
 
 
Exhibit 2-6  Johnson & Johnson GATEWAY 
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Exhibit 2-7 Johnson & Johnson GATEWAY Login Screen 
 
 
Exhibit 2-8  Johnson & Johnson -  Buy Tylenol® Now 
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Exhibit 2-9  Merck-Medco 
 
 
Exhibit 2-10  CIBA Vision® at Novartis 
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Exhibit 2-11  Pfizer Business to Business 
 
 
Exhibit 2-12  EDI Services at Pfizer 
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3.0. Chapter Three:  eBusiness Phases and Models 
Vitale and Weill define eBusiness as marketing, buying, selling, delivering, 
servicing, and paying for products, services, and information across networking linking 
an enterprise and it prospects, customers, agents, suppliers, competitors, allies, and 
complementors.28  This statement captures the essence of eBusiness and applies directly 
to the pharmaceutical industry where firms can use the Internet and IT to establish 
relationships with organizations that perform business with them.  Furthermore, 
eBusiness applies to all the pharmaceutical phases in chapter one. 
3.1. True eBusiness 
 
Paul Stodden, President of Siemens Business Service, projected that true 
eBusiness will emerge after 2005.29  Mr. Stodden further explained that by this time 
eBusiness interactions amongst firms will be wider, products will be more mature, firms 
IT competencies will be further improved, and faster bandwidth and improved IT 
infrastructure will make eBusiness closer to what it was meant to be.  This statement by 
Mr. Stodden has great value and applies to many industries, in specific, pharmaceutical.  
Pharmaceutical companies are already expediting eBusiness and as this business model 
matures further in the next two years, it will be interesting to see which pharmaceuticals 
will be in positioning themselves correctly.  This research delves on technologies and 
trends that pharmaceuticals will embrace in the next few years so that when true 
eBusiness does arrive, who will be the winners and who will be the losers in that industry. 
                                                
28 Peter Weill and Michael Vitale, Place to Space: Migrating to eBusiness Models, Harvard Business 
School Press, 2001, p. 5. 
29 MIT Sloan, Management of Technology Program (2003), International Trip, Siemens Visit (Munich, 
Germany), January 2003. 
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3.2. eBusiness Phases 
 
eBusiness and IT play a major role in all aspects of a pharmaceutical companys 
value chain.  eBusiness initiatives can be distinguished in various categories in terms of 
which phase of the formal work process it fits into the pharmaceutical firm strategy.   The 
following e-initiatives in Figure 3-1 encompass all aspects of the process a 
pharmaceutical firm has to follow to develop and deliver their drugs: 
 
Figure 1 - eBusiness Value Chain in Pharmaceutical industry30     
 
IT plays a crucial role in these eBusiness phases, where vendors and their 
products are critical.  The focus of this research will be on the following phases:  
eProcurement, eSales, and eSupplyChain.  The case studies in this research will analyze 
eBusiness technologies in these phases and see what the prevalent technologies and 
trends are in the pharmaceutical industry.  
3.2.1.  eProcurement 
 
eProcurement can be considered a subset of eSupplyChain.  This generally 
involves buying products online from suppliers.  This could be a one-to-one transaction 
between a supplier and the pharmaceutical firm or as big as an online auction for an 
entire vertical of the pharmaceutical industry.  Michael Porter, a well-known professor at 
Harvard Business School (HBS), claims that procurement using the Internet tends to 
                                                
30 Andrew McAfee, eBusiness at Novartis, Harvard Business School, August 2001, p.16. 
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raise bargaining power over suppliers, though it can also give suppliers access to more 
customers.31  Consequently, pharmaceutical firms seem to be adhering to this advice and 
are investing heavily in eProcurement initiatives.  eProcurement is related to the process 
in which pharmaceutical firms can interact with suppliers in purchasing products needed 
to develop drugs.  Various eProcurement models described by Kalakota include: EDI 
networks, business-to-employee requisitioning applications, corporate procurement 
portals, and Industry consortiums are being actively pursued in the pharmaceutical 
industry. 32 
3.2.2.  eClinical  
 
eClinical is the process in which pharmaceutical firms use the Internet to support 
clinical trails.  Recruiting, for example, is required for clinical trails, and pharmaceutical 
companies can build websites to recruit and filter candidates.  The Internet can serve as a 
powerful media for companies to recruit candidates for their clinical trails.  
3.2.3.  eMarketing and eDetailing 
 
eMarketing and eDetailing are some of the strong points that technology offers to 
pharmaceutical companies.  Firms can build their web presence and brand name to 
develop websites accessible to anyone on the Internet.  Firms offer easy access to 
websites that doctors use for reviewing drugs and other products.  Similarly, electronic 
media such as video conferencing can allow sales representatives to hold meetings with 
doctors while promoting drugs.  Most major pharmaceutical companies have created 
                                                
31 Michael Porter, Strategy and the Internet, Harvard Business Review, March 2001, p. 67. 
32 Ravi Kalakota and Marcia Robinson, e-Business 2.0: Roadmap for Success, Addison-Wesley, Boston, 
2001, p. 310. 
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websites to market their drugs.  Viagra.com and acuvue.com are examples of Pfizer and 
Johnson and Johnson, respectively, marketing their prescription drugs on the Internet.   
3.2.4.  eSales  
 
eSales is used by pharmaceutical companies to sell their products to business 
partners such as doctors, physicians, wholesalers, distributors, and retailers.  Websites 
offer sales capabilities for doctors who can potentially order 24 / 7 / 365.  Additionally, 
pharmaceutical companies can offer promotions to doctors for using the Internet.  eSales 
software can be custom built for certain drugs and products, as opposed to using custom 
software packages to make these sales.  eSales entails providing customer service to 
online buyers as well as analyzing and forecasting their behavior.   
3.2.5.  eLearning  
 
eLearning is the ability for doctors to access pharmaceutical companies over the 
Internet and pursue continued education capabilities.  Many firms offer these capabilities 
to doctors and this creates the opportunity for better relationships between the two.  
eLearning allows the doctors to continue to build their expertise and research additional 
knowledge in their respective fields.   
3.2.6.  eSupplyChain  
 
eSupplyChain allows pharmaceutical companies and their business partners to 
track products throughout the value chain.  SCM is the process that encompasses the 
coordination of order generation, order taking, and order fulfillment / distribution of 
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products, services, or information.33  Automating this process improves the relationships 
between firms and business partners and is a recurring trend in most industries when 
considering the success of companies such as FedEx or UPS.  eSupplyChain integrates 
with suppliers in delivering raw material and other products to pharmaceutical companies.  
Two types of SCM models include pull and push.  In the more traditional push 
model, the merchandise is pushed into the customers hands  in the pull model, the 
customer actually initiates the supply chain.34  Hence, offering the ability for business 
partners to view inventory, orders, and financial data is a preferred eBusiness capability.   
3.3. eBusiness Models 
 
 Four main business models can be pursued by pharmaceutical companies on the 
Internet.  These models are generic to other industries and are typical of most business 
aspiring for the true e in their workflow.  These models are B2C, B2B, Consumer-to-
Consumer (C2C), and mBusiness.   
3.3.1.  Business-to-Consumer 
 
 B2C is one of the simplest models of eBusiness.  Amazon.com is a prime example 
of this model where online buyers can shop from a wide array of products.  This model is 
further enhanced by Amazon which offers customer-reviews of products to build trust 
and credibility of their website.  In the pharmaceutical industry, an example would be the 
ability of consumers to buy from online pharmacies such as CVS.com or other companies 
that deliver OTC drugs to consumers.  The user typically creates a profile on the website 
and enters personal information such as shipping, billing, payment, and address.  This 
                                                
33 Ravi Kalakota and Andrew Whinston, Electronic Commerce: A Managers Guide, Addison-Wesley 
Longman, Inc., 1997, p.287. 
34 Ibid, p.288. 
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transaction is strictly between the business and the consumer who is eventually delivered 
the products.   
3.3.2.  Business-to-Business 
 
 Taylor reveals that B2B is much more complex than the simple B2C model 
because it entails additional complexity for handling activities such as payment handling, 
purchasing, fulfillment, and procurement.   It is mentioned that security, trust, and 
privacy protection are key to building successful eBusinesses.  The overall trend in the 
evolution of eCommerce is towards content management, logistics management, and 
trusted services.35  Another form of B2B is the Enterprise-to-Enterprise (E2E) model 
which allows two or more enterprises to integrate seamlessly for eBusiness integration.  
New software is being developed to establish this niche and has future potential across 
many industries.  Pharmaceuticals can utilize the B2B model to manage eBusiness with 
suppliers, wholesalers, doctors, physicians, and distributors.  This model is much more 
complicated than the B2C and requires more complicated software, hardware, and 
systems integration.   
3.3.3.  Consumer-to-Consumer 
 
Vitale and Weill add an additional item to the list of eBusiness models with C2C.  
This model is pursued in the world-famous online auction site, eBay, which serves to 
connect buyers and sellers online and it charges a nominal fee to consumers.  Yahoo! 
auctions has been successful in Japan, a market from which eBay withdrew last year, in 
building trust with consumers by charging both sellers and buyers and keeping each party 
                                                
35 David Taylor, Doing E-Business: Strategies for Thriving in an Electronic Marketplace, John Wiley and 
Sons, New York, 2001. 
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equally liable for product and payment delivery.  This model is applicable to the 
pharmaceutical industry as connecting buyers and suppliers of pharmaceutical products 
could be a lucrative initiative.  According to Vitale and Weill, successful auctioning 
between businesses has been achieved by FreeMarkets Online and may be a model for 
connecting B2B pharmaceutical companies for auctioning in the future.36  Later case 
studies will reveal that FreeMarkets Online has been actively used by some 
pharmaceutical firms.  
3.3.4.  mBusiness 
 
 mBusiness is an upcoming trend in eBusiness that is rapidly becoming popular in 
Europe and Asia.  Companies such as Japanese NTT DoCoMo have established a suite of 
products and services with i-mode platform that connects mobile users to the Internet.37  
This market is expanding and eventually users worldwide will become comfortable 
buying from the Internet using their cell phones or other handheld devices.  mBusiness 
has some practical applications and services in the pharmaceutical industry.  Integrating 
mobile phones to send electronic prescriptions to patients, for example, is one application.  
Additionally, allowing doctors to be able to refill stock and inventory using handheld 
devices which connect to the pharmaceutical websites could be another example of 
mobile devices being used for eBusiness.  Hence, mBusiness definitely has a future in the 
pharmaceutical industry.  
 The wireless web is being optimized for transactionspushing 
personalizedpreferred information, as well as a variety of applications, to customers.  
                                                
36 Peter Weill and Michael Vitale, Place to Space: Migrating to eBusiness Models, Harvard Business 
School Press, 2001, p. 159. 
37 Harvard Business School Case, NTT DoCoMo: Marketing i-mode, Harvard Business School 
Publishing, Case # 090-502-31, 2002. 
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Furthermore, as the number of mobile Internet users outnumbers PC users worldwide, 
there will be a concomitant shift in eCommerce from wired PCs to Internet-enabled 
mobile devices.38  According to Bergeron, enabling technologies of the wireless Internet 
and the mBusiness model will be: 39 
1. Wireless Networks  
a. Global Systems for Mobile Communications  GSM. 
b. Wideband Code Division Multiple Access  WCDMA. 
c. General Packet Radio Services  GPRS. 
2. Wireless Protocols 
a. Wireless Application Protocol  WAP. 
b. Sun Microsystems J2ME  Java 2 Micro Edition. 
c. Short Messaging Service  SMS. 
3. Symbian Alliance: non-proprietary operating system 
a. EPOCH formed in alliance by major wireless carriers. 
4.  Bluetooth: standard / protocol for short-range wireless communications   
It is clear that there seems to be major potential of the wireless Internet and 
mBusiness.  This is due mainly to the powerful industry alliances and technology 
drivers supporting them. 
B2C, B2B, C2C, and mBusiness are eBusiness models that can be used across all 
industries.  Specifically, they all have useful applications in the pharmaceutical industry.  
It seems that with the exception of C2C, the other three eBusiness models have the most 
                                                
38 Bryan Bergeron, The Wireless Web: How to Develop and Execute a Winning Wireless Strategy, 
McGraw Hill, 2001, p.40. 
39 Ibid, pp. 36-37. 
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traction in the pharmaceutical industry.  Subsequent case studies in this research will 
determine which ones are being more actively pursued than others. 
3.4. Conclusion 
 
There are many phases of eBusiness and how they pertain to the pharmaceutical 
industry.  eBusiness phases in the pharmaceutical industry consist of eProcurement, 
eClinical, eMarketing, eSales, eLearning, and eSupplyChain.  This research will focus on 
eProcurement, eSales, and eSupplyChain.  eBusiness models include B2B, B2C, C2C, 
and mBusiness, all of which may be implemented at pharmaceutical companies.   
After describing eBusiness phases and models in this chapter, the following 
chapter continues the discussion with eBusiness architecture and its components.  
eBusiness architecture consists of several components that are made up of software 
products.  These software products have been developed by well-known vendors who are 
at the forefront of creating eBusiness technologies.  Certain emerging technologies that 
may impact eBusiness in the near future will also be mentioned. 
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4.0. Chapter Four:  eBusiness Architecture and 
Software 
 
Kalakota describes eBusiness architecture in terms of Infrastructure and 
Infostructure.  These so-called interlocking layers create the eBusiness architecture.  
eBusiness Infostructure includes web servers, databases, middleware, and application 
servers.  eBusiness Infrastructure contains customer relationship management (CRM), 
enterprise resource planning (ERP), procurement, and SCM.  Figure 4-1 contains an 
abridged version of Kalakota layers of eBusiness architecture.  
 
Figure 4-1  eBusiness Layers40 
 
These two layers containing specific eBusiness components will be the focus of 
this chapter.  Later cases studies in this research will discuss eBusiness technologies in 
context of Infostructure and Infrastructure.    
                                                
40 Ravi Kalakota and Marcia Robinson, e-Business 2.0: Roadmap for Success, Addison-Wesley, Boston, 
2001, p. 106. 
eBusiness Infrastructure 
! Customer Relationship Management 
! Enterprise Resource Planning 
! Procurement 
! Supply Chain Management 
eBusiness Infostructure 
! Application Servers 
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! Middleware 
! Web Servers 
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4.1. eBusiness Vendors and Products 
 
 Many vendors have developed products for the eBusiness platform that are being 
used in the pharmaceutical industry.  These vendors will be discussed based on the 
following eBusiness architecture categories:  Infostructure and Infrastructure.  These 
vendors are the market-leaders in their respective segments of eBusiness products and 
technologies. 
4.1.1.  eBusiness Infostructure 
 
Components of the eBusiness Infostructure are the foundation of eBusiness 
implementations.  As depicted in Figure 4-1, this category consists of application servers, 
databases, middleware, and web servers, each of which plays a major role in the 
eBusiness architecture.     
4.1.1.1. Application Servers 
 
Applications servers are the middle-tier of a distributed three-tier application.  
This is a server program that usually contains the business logic of an eBusiness 
application.  The application server interfaces with the front-end (first-tier) of the 
application which is developed using a web-based graphical user interface.  On the other 
side, application servers interface with the application backend (third-tier), which is 
usually a database server, an enterprise system, or a legacy system.  The application 
server is commonly integrated with a web server and they communicate via the Hypertext 
Transfer Protocol (HTTP) or a common gateway interface (CGI). 
Application servers are used by pharmaceutical companies for implementing web-
based initiatives.  Many pharmaceutical firms are building web applications that integrate 
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with enterprise backend systems such as manufacturing, ordering, and distribution.  Most 
application servers have connector architectures for integration with legacy and enterprise 
systems and offer great value to pharmaceuticals looking to implement such initiatives.  
4.1.1.2. Application Server Vendors and Products 
 
There are five main vendors in the application server category.  According to 
Gartner Research, two architectures  Sun Microsystems Java 2 Enterprise Edition 
(J2EE) and Microsofts COM+/.NET  will remain dominantthrough 2006.41  
Application server vendors in Table 4-1 conform to either the J2EE or .NET standards.    
Application Server Vendor Product 
BEA WebLogic 
Sun / iPlanet SunOne 
IBM Web Sphere 
Microsoft COM+ / .NET 
Jboss Jboss 
Table 4-1  Application Server Vendors and Products42 
 
These vendors have a strong reputation of quality product development and their 
application servers deliver eBusiness solutions to numerous industries.   
The BEA WebLogic Platform is a package product (BEA WebLogic Server, 
BEA WebLogic Portal, and BEA WebLogic Integration) that offers a single, 
unified, easy-to-use infrastructure platform for application development, deployment, and 
management.43  This platform allows organizations to develop custom J2EE-based 
applications using an enterprise architecture framework that is secure and easy to mange.  
According to ServerWatch, BEA led the J2EE application server market share at 37% in 
                                                
41 Y. Natis and M. Pezzini, Gartner Research, App Server Vendors: The Magic Quadrant, 26 Oct, 2001, 
p.1.  
42 ServerSide.com, Application Server Matrix, Apr.11, 2003, www.theserverside.com/reviews/matrix.jsp. 
43 Bea.com, March 2003, www.bea.com. 
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2001.44  The BEA WebLogic Server is both an application server and web server and is 
used for both backend and front-end integration for customers.45   
SunOne by Sun Microsystems is a highly scalable and robust foundation for 
traditional software applications as well as current Web-based applications, while laying 
the foundation for the next-generation distributed computing models.46  The SunOne 
technical architecture is shown in Exhibit 4-1.  The SunOne application server resides 
alongside the SunOne web server in the data, application, reports, and transactions layer 
of the SunOne platform.  It communicates with the SunOne office productivity and mail / 
calendar services below, and the directory and portal servers above.  This is an extremely 
robust platform that allows customers to leverage their data and assets as services. 
The IBM WebSphere Application Server is a high-performance and extremely 
scalable transaction engine for dynamic e-business applications.47  IBM WebSphere is a 
J2EE-enabled (Java Server Pages, Enterprise Java Beans, Servlets) application server that 
will be capable of deploying Web Services in the future.  Capabilities include scalability, 
flexibility, rapid development and deployment.  Other features of this application server 
include Java Database Connectivity (JDBC), Web Services support Simple Object 
Access Protocol (Soap), Web Services Definition Language (WSDL), and Universal 
Description Discovery and Integration (UDDI) client, Java Security, and Java Naming 
Directory Interface (JNDI).48 
                                                
44 Natasha Gray, BEA Holds Lions Share of J2EE App Server Market, www.serverwatch.com, 
September 2001. 
45 Bea.com, March 2003, www.bea.com/framework.jsp?CNT=index.htm&FP=/content/products/platform/ 
46 Sun.com, Sun Open Net Environment (Sun ONE), wwws.sun.com/software/sunone/. 
47 IBM.com, January 2003, www.ibm.com. 
48 IBM.com, IBM Websphere software platform, March 2003, www-
3.ibm.com/software/info1/websphere/index.jsp?tab=products/appserv. 
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 The Microsoft .NET Enterprise Servers suite consists of a variety of products that 
can be used to deliver web-based applications and web services.  These products include 
the application center for developing web application, the BizTalk Server for integration 
with businesses partners, and the Commerce Server for developing custom e-Commerce 
solutions.  These servers communicate with other products in .NET Enterprise Server 
suites that include databases, email, mobile, portal, and network servers.  
 Jboss is a free application server that was originally developed in the Apache 
open source initiative.  This application server is J2EE-compliant and was built by 
programmers in a community-wide setting.  It has rapidly become popular and its 
scalable and robust architecture has made it an application server of choice in 
organizations with limited eBusiness and IT budgets.  Jboss initiatives include future 
integration with other platforms such as Microsoft .NET. 
 It is clear that several players in the application server market include Sun, BEA, 
IBM, Microsoft, and the emerging Jboss.  These application servers are being rapidly 
deployed in eBusiness architectures in the pharmaceutical industry and they all deliver 
the scalability and robustness that the systems require.   
4.1.1.3. Databases 
 
A database management system is defined as a collection of enterprise data that a 
firm organizes in a clear and concise manner so that it can be accessed, modified, and 
managed easily.49  eBusiness data contains information related to products, prices, users, 
customers, and vendors.  Databases are accessed using the Structured Query Language 
(SQL), which is a standard language for improvising interactive queries against the 
                                                
49 WhatIs.com, April 2003, www.whatis.com.  
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database to perform operations such as selects, updates, deletions, and insertions.  
Perhaps the most commonly used database in the industry is the relational database in 
which data is stored in a tabular format so that it can be organized and accessed easily.   
Pharmaceutical firms realize the inherent necessity and use of databases.  
Databases store critical business information.  Pharmaceuticals use data for drug 
discovery, clinical trials, procurement, web-based initiatives, and other important 
components of their value chain.  Furthermore, databases can store information related to 
products, suppliers, pricing, and vendors for eBusiness initiatives.  Hence, databases add 
value to pharmaceuticals for numerous facets of their business.    
4.1.1.4. Database Vendors and Products 
 
Several vendors have dominated the database market.  This is a mature product in 
a market that has been instrumental in delivering IT infrastructure.  Table 4-2 contains 
some of those vendors and their products.  Vendors like IBM and Microsoft, for instance, 
have more than one database product, and that usually reflects the organizations business 
needs and size of data needed to be stored.   
Database Vendor Product 
Oracle Oracle 
IBM DB2, Informix 
Microsoft SQL Server, Access 
Sybase SQL Anywhere 
Table 4-2  Database Vendors and Products 
 
Oracle is one of the market leaders when it comes to database products.  
According to CFO of Oracle, Todd Henley, the Oracle database still accounts for 60% of 
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their annual sales.50  Exhibit 4-2 depicts the Oracle 9i database architecture.  The Oracle 
database is a reliable database platform that handles eBusiness transactions in a secure 
and manageable way.  Moreover, this database is known for storing content information, 
data integration, and business intelligence. 
IBMs original database product was DB2 that was used in mainframe 
applications, and their purchase of Informix has brought them another reputable database 
product.  DB2 is IBMs reliable scalable, and high-performing database that is built on 
open standards for ease of access and sharing of information for  developing and 
deploying critical solutionsthere are more than 60 million DB2 users from 400,000 
companies worldwide relying on IBM DB2 Information Management technology.51  
IBM has created an eBusiness suite based on DB2 and is an enterprise whose business 
processes are integrated end-to-end across the company and with key partners, suppliers 
and customers. It is an enterprise that can respond with flexibility and speed to any 
customer demand, market opportunity or external threat.52  IBMs Informix relational 
database offers data management software for data warehousing, analysis and reporting, 
Web content delivery, and broadcasting from a digital media library.53      
Microsoft develops two major database products including the industry-wide 
business database, SQL Server, and Access which is the less scalable database product.  
Microsoft SQL Server 2000 Enterprise Edition is the complete database and analysis 
offering for rapidly delivering the next generation of scalable e-commerce, line-of-
                                                
50 MIT Sloan, MOT Program (2003), West Coast Trip, Oracle (Redwood Shores, CA), March 2003. 
51 IBM.com, March 2003, www-3.ibm.com/software/data/db2/. 
52 IBM.com, March 2003, www.ibm.com, http://www-3.ibm.com/software/data/e-business/. 
53 IBM.com, March 2003, www.ibm.com, www-3.ibm.com/software/data/Informix/. 
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business and data warehousing solutions.54  Its benefits include scalability reliability, 
performance, and fast time-to-market.  On the other hand, whether users are creating a 
stand-alone desktop database for personal use, departmental use or for an entire 
organization, Access offers an easy-to-use database for managing and sharing data.55  
Benefits of Microsoft Access include simple connectivity to information, web-enabled 
information sharing capabilities, and ease of use and deployment.  
The Sybase database servers, include Sybase Adaptive Server which is a 
powerful data management platform designed for transaction-intensive enterprise 
applications, with advanced capabilities to meet the evolving requirements of e-
Business, 56 and  SQL Anywhere which is a comprehensive package that provides data 
management and enterprise synchronization to enable the rapid development and 
deployment of distributed e-Business solutions.57  Both these products from Sybase 
deliver database management capabilities for eBusiness solutions that require rapid 
development and deployment.   
In review, various database products developed by vendors like Oracle, IBM, 
Microsoft, and Sybase offer core functionality for eBusiness implementations.  These 
products are all known for performance, scalability, reliability, and ease of use.  
Databases are a well-established market in terms of their role in IT infrastructure and they 
consist of several main players who own a majority of the market share.   
                                                
54 Microsoft.com, Microsoft SQL Server 2000, April 2003, 
www.microsoft.com/catalog/display.asp?subid=22&site=10145. 
55 Microsoft.com, Microsoft Access 2000, April 2003, 
www.microsoft.com/catalog/display.asp?subid=22&site=769 
56 Sybase.com, Products: Database Servers, April 2003, www.sybase.com/products/databaseservers. 
57 Ibid. 
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4.1.1.5. Middleware 
 
Middleware is used to refer to the underlying technologies that implement 
component-based-development(using) the Common Object Request Broker 
Architecture (CORBA) specificationsby the Object Management Group (OMG).58  
Basically, middleware is a set of programs that exist to connect or provide a link between 
two already existing applications.  Middleware is often described as a so-called glue-
together of programs that may contain data which can be consolidated to provide useful 
information.  Middleware provides messaging services between programs residing on 
different networks.  Messaging models communicate with a messaging server and offers 
application the ability to interact with applications using standardized message codes as 
well as communicating across different programming environment.  Messaging can be 
achieved using a publish / subscribe model or a point-to-point model.  IBM with the MQ 
Series and Sun Microsystems with its Java Messaging Service (JMS) dominate the 
message exchange products market.   
Middleware is sometimes referred to as the enterprise application integration 
(EAI) model because they connect distinct systems on the network.  EAI is the point-to-
point integrationmost often used to normalize data from a source to a destination.59  
Although EAI and middleware are used to connect CRM and ERP packages, they do 
require complex programming and connector applications.  Hence, middleware is a 
solution for connecting, upgrading, and coordinating business applications that the 
enterprise owns.  
                                                
58 Alex Nghiem, IT Web Services:  A Roadmap for the Enterprise, Prentice Hall, New Jersey, 2003, p. 17. 
59 Ibid, p. 26. 
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Since eBusiness solutions have not been implemented as rapidly in 
pharmaceuticals as say other industries like financial services or retail, many 
pharmaceutical firms still own disparate backend systems programmed in a variety of 
environments.  These systems can be connected via the middleware architecture, and 
hence save the pharmaceutical firms the additional effort of rebuilding these systems 
from scratch.  Hence, middleware technologies have potential in the pharmaceutical 
industry.   
4.1.1.6. Middleware Vendors and Products 
 
Vendors in the middleware category of eBusiness Infostructure are shown in 
Table 4-3.  Since there is tight integration between application servers and the 
middleware products, three of the four vendors mentioned in this Table 4-3 are 
prominent members of the application server list as well.   
Middleware Vendor Product 
BEA Tuxedo and MessageQ 
TIBCO ActiveEnterprise 
IBM Eclipse 
Sun SunOne 
Table 4-3  Middleware Vendors and Products 
 
The SunOne architecture is Sun Microsystems middleware product.  This consists 
of the application server, web server, security, and directory server.  Exhibit 4-1 shows 
this architecture that allows seamless integration between clients and enterprise systems 
over distributed networks.  
BEA Tuxedo is their middleware product that integrates with the enterprise 
legacy data and corporate applications to deliver a complete eBusiness solution.  Another 
BEA middleware product is the BEA MessageQ, which is built on a queued messaging 
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technology that allows and guarantees communication amongst heterogeneous 
applications using messaging technologies.  Exhibit 4-3 and Exhibit 4-4 show depictions 
of the BEA Tuxedo and BEA MessageQ Application Programming Interface (API), 
respectively. Both Tuxedo and MessageQ make BEA one of the leaders in the 
middleware market for developing eBusiness solutions. 
Tibco offers B2B integration (that) makes interactions between companies more 
efficient and cost-effective by enabling secure exchange of information over the Internet 
and streamlining business processes that involve multiple organizations.60  The Tibco 
ActiveEnterprise product offers a complete line up of eBusiness components that allows 
an organization to connect networks, databases, and other information stores.  
Components of the ActiveEnterprise include messaging, deployment, adapters, and 
content distribution capabilities.   Other products include Business Activity Monitoring 
(BAM) which is the ability to monitor internal and external business activities of an 
organization.  Tibco products offer data aggregation and analysis capabilities which 
pharmaceutical firms can enjoy.  Finally, Tibco offers Business Process Management 
(BPM) which allows companies to manage resources and tasks which are the components 
of business processes.  Tibco products support the J2EE platform and use the Java 
Connector Architecture, EJB integration, and JMS.  These products provide integration of 
distributed applications that include mainframe and enterprise applications in the backend.   
IBMs released the Eclipse software that consists of software for deploying, 
securing, integrating and managing e-business data and applications, including Web 
services.  Specifically, the tools support WebSphere, Lotus Domino, CrossWorlds, DB2, 
                                                
60 Tibco.com, Business-to-Business Integration, April 2003, 
www.tibco.com/solutions/technology_solutions/b2b/default.jsp?m=c12. 
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Tivoli, MQ, and IBM eServer iSeries.61  Lotus Domino allows the connection to build 
front-end applications that connect with the WebSphere application server to retrieve data 
from the Domino database.  CrossWorlds is a suite of products that allows business 
process integration and development of process collaborations.  Tivoli allows 
administrators to monitor application running on different operating systems such as 
UNIX and Windows. MQ serves as a broker for integration between distributed 
applications.  Finally, the iSeries product allows inexperienced web developers to create 
web-based applications using automated tools 
4.1.1.7. Web Servers 
 
A web server offers the capability to deliver files that compose web pages in 
eBusiness applications to be delivered to web browsers.  Web pages often interact with 
application servers or databases via CGI and invoke queries on applications residing on 
multiple tiers.  The CGI programs then parse the results of the queries and return a 
consolidated web page to the browser that invoked the original request.  Exhibit 4-5 
shows the technical architecture of a Java-based web server.  This diagram demonstrates 
the connections between the client that issues an HTTP request to the web server, which 
contains the Servlets engine as well as the JDBC drivers to connect to the database in the 
backend.  The web server is responsible for handling the request, sending it to the 
backend database or data store, to finally sending the response back to the client.   
 Ever since the emergence of the Internet, web servers seem to have been utilized 
by many firms in the pharmaceutical industry.  As shown in previous chapters, all major 
players in this industry have websites being rendered by web servers.  Most of these 
                                                
61 IBM.com, WebSphere Software Platform, March 2003, www-
3.ibm.com/software/info1/websphere/index.jsp?tab=news/ibmnews/pr020610a. 
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websites are strictly information and were developed to establish a web presence.  Other 
pharmaceutical companies have taken web server to a higher level and integrated them to 
application servers in developing eBusiness initiatives.  These concepts will be discussed 
in subsequent case studies in this research.    
4.1.1.8. Web Server Vendors and Products 
 
Several vendors are prominent in the web servers market. Table 4-4 contains a 
list of the major database products in the industry.  These web servers integrate tightly 
with application servers and it seems the market space is being controlled by dominant 
players such as Microsoft, Sun, and BEA. 
Web Server Vendor Product 
Microsoft  Internet Information Service (IIS) 
Apache Tomcat 
Sun SunOne Web Server (iPlanet) 
BEA BEA Web Logic 
Table 4-4  Web Servers Vendors and Products 
 
 Web Servers have evolved over the years and in certain cases, application servers 
and web servers are being bundled as one product.  Microsoft IIS is a popular web server 
for rendering web application to clients on the Internet.  This product has evolved over 
the years and is currently offering web-based interaction to other devices such as mobile 
phones and PDAs.  BEA WebLogic Server serves as both the application server and the 
HTTP web server.  This product is being deployed for many eBusiness solutions to 
integrate with databases and enterprise systems in the backend and handle requests from 
the front-end.  The SunOne Web Server (formerly iPlanet / Netscape) is another high-
performing web server that belongs to a powerfully architected product line.   
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The Tomcat web server is a free web server developed as part of the Apache open 
source initiative and is rapidly being deployed in organizations that need a web presence 
but are seeing shortfalls in their IT infrastructure budgets for web initiatives.  The Apache 
Tomcat web server is described as  a commercial-quality server solution based on the 
Java Platform that supports the Servlet and JSP specifications. Managed by the Apache 
Jakarta Project, it is developed in an open and cooperative fashion.62  Apaches market 
share of web servers was 62% in 2002.63  In summary, the Apache open source web 
server is a free and highly-utilized product on the Internet. 
The concept of free software started at the Artificial Intelligence (AI) Labs at MIT 
in 1984 under the supervision of Richard Stallman as the GNU project which envisioned 
no one ever having to pay for software.  This software was protected by the GNU 
General Public License (GPL).  After more than a decade, in 1997 the concept of Open 
Source emerged and this allowed more mixing of proprietary and open source software 
and was protected by the Open Source license.  Open Source offers the following criteria:  
free redistribution, availability of source code, and ability of derived works, and 
distribution of the Open Source license.64  
In review, application servers, web servers, databases, and middleware are 
important components in establishing fundamental eBusiness in the pharmaceutical 
industry.  Application servers serve as the middle tier between the user front-end and 
backend enterprise systems.  Web servers render pages that make up the front end of the 
eBusiness solution to be viewed in browsers.  Databases are extremely critical because 
                                                
62 Java Guru, Tomcat FAQ Home, April 2003, www.jguru.com/faq/Tomcat. 
63 Server Watch, Netcraft Survey Highlights, www.serverwatch.com, December 2002. 
64 Chris DiBona, Open Sources: Voices from the Open Source Revolution, Sam Ockman, OReilly, 1999, 
California, pp. 2-3, pp. 176-179. 
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they store eBusiness data of firms and they are a well-established technology.  Finally, 
middleware allows disparate backend systems to be integrated.  Case studies in this 
research will reveal that many of these eBusiness Infostructure components are being 
utilized in the pharmaceutical industry. 
4.1.2.  eBusiness Infrastructure 
 
 eBusiness Infrastructure exists above the aforementioned Infostructure layer and 
consists of the important components such as CRM, ERP, procurement, and SCM.  
Pharmaceutical firms use technology for all these phases of their business.  eBusiness 
infrastructure in portrayed in Exhibit 4-9 with regards to the relationship between the 
supply chain, traditional enterprise, and demand chain modules of enterprise software. 
4.1.2.1. CRM 
 
CRM is an industry-wide term used to describe the way an organization can 
manage relationships with their customers using web-based software and methodologies.  
Customers are one of the most important members of an organizations value chain and 
automating and handling their requests using technology can lead to success.  Customer 
information is stored in databases so that salespeople, management, and customer service 
representatives can readily access it.   
CRM offers critical benefits to employees and account managers related to 
marketing and knowledge-sharing.  Customer data, for example, can be used by the 
marketing department to formulate a marketing campaign and segmenting the customers.  
Similarly, electronic knowledge-sharing amongst account managers, product manager, 
and sales representatives is equally valuable to the firm.   CRM systems can be utilized 
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for analyzing customer data such as most profitable ones.  In addition, CRM can 
streamline existing processes such as offering the ability for sales representatives to take 
orders using their mobile devices such as cell phones and personal digital assistants 
(PDAs).  This data is also helpful for understanding customer needs and proactively 
improving relationships with them.  As a result, CRM provides key benefits to the 
organizations that implement them as part of their eBusiness strategies. 
Pharmaceuticals can find many benefits in CRM.  Being able to handle 
relationships with business partners such as doctors, distributors, and retailers can 
improve these important relationships.  Customer service representatives can use this 
software in pharmaceutical call centers and this data can be analyzed further by strategy 
and marketing groups, who can then determine what products customers are looking for.  
Finally, the ability for salespeople to place orders for doctors from mobile devices while 
they are on the road is a typical use of a CRM in the pharmaceutical industry. 
4.1.2.2. CRM Vendors and Products 
 
According to Gartner Research, CRM market in 2002 was down nearly 20% from 
the previous year.65  This is related to decreasing CRM budgets in organizations and 
declining new licenses.  The following vendors in Table 4-5 control of the CRM market.   
CRM Vendor Product 
Siebel Siebel eBusiness Applications 
SAP mySAP CRM Pharmaceuticals 
PeopleSoft PeopleSoft Customer Relationship Management  
E.piphany E.piphany CRM 
Table 4-5  CRM Vendors and Products 
 
                                                
65 Thomas Topolinski, Prediction 2003: CRM Market Faces Tough Times, Gartner Research. 
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 Siebel is one of the market leaders of CRM software.  Siebel software products 
are shown in Exhibit 4-6.  Siebel products focus on sales, marketing, and customer 
service.  These products include functionality such as sales, marketing, interactive selling, 
partner and employee relationship management, analytics, mid-market, universal 
application and market networks, and industry applications.  These applications are 
available as web clients and this complete package offers many ways a pharmaceutical 
company can improve and manage their relationships with their clients.66    
 mySAP CRM is SAPs product that focuses on providing organizations the ability 
to deliver value to the customer and achieve profitable growth in that process.  mySAP is 
a solution (that) connects front- and back-office functions into a single, customer-centric 
operation. And enables collaboration among employees, partners, and customers by 
providing relevant, personalized information from multiple data sources and business 
processes.67  SAPs goal is to deliver a product that can connect business partners, 
employees, technology, and processes in an organization.  The four dimensions covered 
by this product suite are connecting business to consumers, connecting employees to the 
business, collaboration between business and partners, and identifying industry-specific 
needs.  The mySAP CRM pharmaceutical software allows companies to maintain 
customer relationships, identify customer potentials and market share, provide superior 
customer service, and plan and execute sales and marketing campaigns.68  These are key 
benefits that CRM packages deliver to pharmaceuticals.  In summary, mySAP provides 
                                                
66 Siebel.com, Employee Relationship Management, April 2003, 
www.siebel.com/products/erm/product_module_descr.shtm#total. 
67 SAP.com, mySAP Customer Relationship Management, April 2003, www.sap.com/solutions/crm/. 
68 SAP.com, SAP for Pharmaceuticals, April 2003, 
www.sap.com/solutions/industry/pharm/keycapabilities/. 
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faster decision-making for customer service representatives and improved customer 
satisfaction.   
A world-leading dental equipment manufacturer, Heraeus Kulzer GMBH, 
implemented a mySAP CRM system in less than a year to present a single face to its 
customers, namely 45,000 dentists and 9,000 dental technicians.  Using mySAP CRM, 
Kulzer was able to make sure that customer service is efficient and effective throughout 
all its channels(using) informative customer profiles with detailed information on 
customer history, main points of interest, and service requests to build lasting customer 
relationships with new customers  and gain market share.69  It is evident that mySAP 
CRM provides numerous benefits related to improving customer relationships for 
pharmaceutical companies. 
 PeopleSoft CRM, of which the Advisor product is depicted in Exhibit 4-7, is a 
complete suite of products that cover a broad spectrum such as sales, marketing, help 
desk, support, and telemarketing.  The products of interest to pharmaceuticals in terms of 
their eBusiness phases include online marketing, order capture, sales, mobile sales, and 
multi-channel integration.  All these products offer real-time intelligence for quick 
decision-making opportunities for customer service representatives and salespeople.70  
 E.piphany states that they are offering the next generation of CRM software that 
delivers marketing, sales, and services.  This product is based on the J2EE platform and is 
designed in a modular fashion.  This suite offers customers and their service 
representatives to undergo a personalized experience during their interaction.  
                                                
69 SAP.com, SAP for Pharmaceuticals: Customer Successes, April 2003, 
www.sap.com/solutions/industry/pharm/customersuccess/ 
70 PeopleSoft.com, April 2003, www.peoplesoft.com. 
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E.piphanys strength is its ability to integrate with backend financials, legacy, or ERP 
systems.  Front-end to E.piphany products can be kiosks, branches, Internet, or wireless. 
4.1.2.3. ERP 
 
ERP is a set of application software that consists of many modules related to 
business activities such as manufacturing, purchasing, inventory, customer service, order 
tracking, human resources, and financials.  ERPs are an integrated system that embodies 
the newly understood tight interdependencies among a firms functional units.71  An 
ERP system is naturally coupled with a relational database that stores the enterprise data.  
In order to successfully implement an ERP system, organizations overhaul their business 
processes and mandate extensive staff-training to effectively use the new software.   
Pharmaceutical firms can find ERP packages quite useful in storing information 
related to purchasing and financials.  Most pharmaceutical firms own global operations 
and properly implemented ERP systems can deliver consolidated data related to suppliers, 
orders, revenues, and sales to management and executives.  This data can be beneficial 
for reducing cost, consolidating suppliers, and tracking geographic sales. 
There are several challenges related to ERP systems and their implementations in 
large enterprises.  According to a Forrester Research, during an informal survey at a 2001 
B2B technology leadership forum, more than 500 participants indicated that only 6% 
consider their ERP systems to be very effecting at helping them collaborate with partners, 
while 79% said that their ERP systems were not effective or somewhat effective.72  
Additional survey data revealed that more than half of the participants had already 
implemented an ERP and that many were not sharing ERP data with suppliers, and would 
                                                
71 Jeanne Ross, The ERP Revolution: Surviving Versus Thriving, MIT, Research Paper, November 1998. 
72 Jennifer Chew, Making ERP Work (Interviews), Forrester Research, Inc., June 2001. 
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expect to do so by 2003.  Other constraints of ERP systems included inability to locate 
orders, share status of inventory with suppliers, and capacity constraints.  These 
constraints could be attributed to lack of an enterprise backbone / networks (Extranets) 
that included collaboration with suppliers, distributors, wholesalers, and other business 
partners.   
Advantages of ERP systems, however, seem to dominate this discussion.  ERP 
provides employees the ability to gather operational insights on their business, meeting 
production material requirements, establish contracts with suppliers, and view complete 
order status throughout the manufacturing and distribution process.  Looking ahead, ERP 
implementations will enhance cross-enterprise collaboration, unification of ERP vendors 
(which currently has more than a dozen dominant players), and creation of enterprise 
backbones amongst business partners.73 
4.1.2.4. ERP Vendors and Products 
 
Major vendors in the ERP market space are shown in Table 4-6.   
ERP Vendor Product 
SAP mySAP ERP 
PeopleSoft Enterprise Performance Management 
Enterprise Service Automation 
Financial Management Solutions 
Human Capital Management 
J. D. Edwards Financial Management  
Inventory Management 
Workforce Management 
Order Management 
Oracle Marketing 
Financials 
Human Resources 
Products 
Order Management 
                                                
73 Ibid. 
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Table 4-6  ERP Vendors and Products 
 
SAP AG is one of the leading vendors delivering ERP software.  The mySAP 
ERP product offers a complete solution that allows the management of financials, human 
resources, and organizational resources.  These solutions increase efficiency by leverage 
existing IT assets as well.  According to an SAP press release, the mySAP ERP is 
powered by SAP® NetWeaver, the industrys leading integration and application 
platform,  (and it ) is fully interoperable with Microsoft .NET and IBM WebSphere 
and supports portal and mobile technology, business intelligence, and knowledge 
management.74  It is evident that the SAP ERP package is focused on seamless 
integration with other eBusiness platforms that are part of the eBusiness Infostructure.  
The relevant industry solution is called mySAP Pharmaceuticals.  This product offers 
benefits to pharmaceuticals and includes functionality such as electronics signatures for 
audit trails, unit and recipe management, version and process control, and data approval.   
PeopleSoft offers the following products that can be used for enterprise resource 
planning:  enterprise performance management (EPM), enterprise service automation 
(ESA), financial management solutions (FMS), and accelerated human resources (AHR).  
EPM allows employees, customers, and suppliers to connect using portals and set 
organizational goals and create metrics and plans to measure them.  EPM delivers the 
capability to optimize project investments of an organization.  FMS offers the ability to 
create a pure Internet-based suite of financial applications. HCM includes human 
resource management functionality and allows an organization to manage and allocate 
                                                
74 SAP.com, SAP Extends ERP Offering, Defines Best-in-Class ERP Solution, March 12, 2003, 
www.sap.com/company/press/press.asp?pressID=2089. 
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resources globally.  In review, PeopleSofts ERP software covers all major functionalities 
necessary for developing a pharmaceutical eBusiness solution.  
A midsize pharmaceutical company, Millennium Inc., implemented a new human 
resources system using the PeopleSoft AHR package solution.  This system replaced an 
outdated legacy system and was implemented in nearly 100 days.  The new system was 
inevitable because Millenniums employee headcount had doubled in less than a year.  
The new PeopleSoft HR system reduced HR managers overhead administrative tasks 
and automated activities such as payroll, visa processing, and vendor-relations.  The 
success of this project is evident that for every 25% increase in employee population, HR 
staff would only need to be increased by 10%.  Hence, PeopleSoft offers complete ERP 
package solutions that improve enterprise-wide business processes such as HR.75 
J. D. Edwards offers a wide variety of ERP software, however, the ones most 
pertinent to pharmaceutical firms includes the following:  financial management, 
inventory management, workforce management, and order management.  These products 
cover the enterprise foundation, assets, people, and fulfillment categories, respectively.  
These components allow an organization to measure the value provided by assets, 
resources, and projects. 
Grupo Framanova, a leading pharmaceutical company in Latin America, 
implemented a J.D. Edwards financial, distribution, and human resource ERP packages in 
the late 1990s.  This Costa Rican company has developed more than 2,500 products and 
has nearly 500 active customers in that region.  The key drivers for this decision were to 
reduce cost, improve profitability, and have real-time information available throughout 
                                                
75 PeopleSoft.com, Millennium Pharmaceuticals Supports Growth with PeopleSoft Accelerated Solution, 
www.peoplesoft.com/corp/en/products/mid/case_studies/millenium.jsp, March 2003. 
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the organization.  The two year implementation resulted in better management of 
customer data, integrated data throughout the organization, improved inventory-
coordination, and improvement management of scientific information.  Thus, J.D. 
Edwards ERP products provide a viable solution to pharmaceutical companies.76 
The Oracle E-Business Suite is a complete set of business applications that 
enable (organizations) to efficiently manage customer interactions, manufacture products, 
ship orders, collect payments and more - all from a business system that shares a single 
technology foundation.77  This platform can be implemented as a singular unit or 
multiple modules that seamlessly collaborate with each other.  The overall benefit of this 
product suite is that it reduces cost and expenses, improves business processes, and 
allows the organization to make better enterprise decision for their business.  According 
to research at Stanford University, Oracle is one of the top five ERP vendors in that 
market with about ½ the revenues of the leader, SAP.78   
4.1.2.5. SCM and Procurement 
 
SCM utilizes sophisticated software to manage the flow of product, information, 
and finances as they go from the suppliers to manufacturers, to distributors or retailers, 
and finally to consumers.  The success of a SCM system is determined by the level at 
which inventory is controlled.  Managing the flow of goods from the suppliers all the way 
to the customers is related to the information aspect of a SCM system.  Information flows 
consists of information related to updating order and delivery status information as well 
                                                
76 J.D.Edwards, With J.D. Edwards, Grupo Framanova, Intermed Increases Sales and Improves 
Processes, www.jdedwards.com/content/enUS/Customer-Customers/GrupoFarmanova.pdf, April 2003. 
77 Oracle.com, E-Business Suite, www.oracle.com/applications/index.html?content.html, March 2003. 
78 Eric Marti, SAP and the Online Procurement Market, March 2000, Graduate School of Business 
Stanford University, Case Number: EC-5. 
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as the ability to track orders.  The financial flow of a SCM system contains information 
related to payments, credits, and other financial data that is part to the value chain.  Firms 
can differentiate the process of implementing a SCM system by delivering either a 
planning application or an execution application.  While planning applications use 
sophisticated methodologies and techniques to fulfill orders, execution applications allow 
the users to track good over the various stages of the supply chain process.  Hence, SCM 
systems can be quite useful for managing complex processes over the entire business 
value chain.   
Pharmaceutical companies can see lots of opportunity in developing SCM 
systems.  For instance, a SCM system at a pharmaceutical firm can allow the company 
and its suppliers to track the status of goods such as chemicals and whether they have 
been delivered or in transit.  Additionally, pharmaceuticals can effectively manage their 
inventories with such systems.  Finally, SCM systems allow the distributors, wholesalers, 
retailers, and internal customer services representatives to track orders after they have 
been shipped from the pharmaceutical company.  Benefits of SCM systems to 
pharmaceuticals include order tracking, improved business relationships, and efficient 
inventory control.   
4.1.2.6. SCM and Procurement Vendors and Products 
 
The SCM market is expected to undergo major changes in the near future.  
According to the Yankee Group, this $1.9 billion market will see a shakeout of vendors 
in which ERP vendors like PeopleSoft and Baan will emerge, and incumbent vendors 
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such as i2 and Manugistics will have to recreate their strategies and product offerings, 
otherwise they will continue to see a decline of their market share.79  
Pharmaceuticals can use SCM and Procurement software to manage relationships 
with suppliers, manage their supply chain network, and improve relationships with 
customers.  Major vendors in the SCM and Procurement market space are listed in Table 
4-7.   
SCM /  Procurement  Vendor Product 
SAP mySAP SCM Pharmaceuticals 
i2 Technologies i2 SCM 
Manugistics Manugistics SCM 
  
Ariba Ariba Procurement Solution 
Commerce One Commerce One Procure 
SAP mySAP eProcurement 
Table 4-7  SCM Vendors and Products80 
 
According to the Yankee Group, SAP is the dominant vendor of SCM software.  
Their product handles the planning, execution, and management of events that often 
interfere with supply chain excellence.81  The mySAP SCM product line allows 
organizations to efficiently operate their supply chain and effectively deliver products to 
their customers.  mySAP SCM for pharmaceuticals allows organization to integrate their 
extended supply chain with features such as 24 / 7 manufacturing, collaborative 
transportation, supply and production planning, dangerous goods handling, and more.82  
SAP declares the following three business benefits of their SCM products:  reduced cost, 
increased revenue, and customer retention.    
                                                
79 Michael Dominy, Supply Chain Management Software Shakeout to Speed Up, Feb. 11, 2003, Yankee 
Group. 
80 Chad Eschinger, Gartner Group, Prediction 2003: Supply Chain Management Realigning, 11/02. 
81 SAP.com, mySAP Supply Chain Management, April 2003, www.sap.com/solutions/scm/ 
82 SAP.com, SAP for Pharmaceuticals: Key Capabilities, April 2003,  
www.sap.com/solutions/industry/pharm/keycapabilities/ 
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Additionally, mySAP SCM offers collaborative procurement capabilities that 
allow pharmaceutical organization to streamline the the entire procurement process for 
direct materials(including) strategic sourcing agreements form the basis of highly 
automated procurement planning and execution(such as) automated sourcing and 
scheduling are highly adaptable.83  In term of suppliers, organizations can use this 
product for automatic suppliers selection as well as identifying new ones with new 
products.  Bidding capabilities allows buyers to place bid invitations on services and 
materials.  Moreover, collaborative procurement in mySAP SCM offers covers ordering, 
invoicing, and transportation.  mySAP procurement is part of a new e-Commerce 
strategyfor online procurement software and services  tools that enabled companies to 
automate and mange their purchases of operating resources (i.e. goods and services 
such as office supplies, furniture, travel services, etc., which were not direct input into a 
companys products.).84  Hence, SAPs entry in the procurement market was to build its 
product portfolio of enterprise application software in the supply-chain module. 
i2 Technologies delivers SCM products based on templates catered towards 
specific industries.  The i2 products for pharmaceuticals offer improved customer 
services and quicker product launches in the market.  The benefits provided by i2 
products include improved sales through forecasting, improved utilization of assets, 
reduced inventory costs, reduced logistic expenses, and reduced transportation costs.  The 
i2 SCM software allows companies to plan and execute supply to meet customer 
                                                
83 SAP.com, mySAP Supply Chain Management: Collaborative Procurement, April 2003, 
www.sap.com/solutions/scm/keycapabilities/procurement.asp. 
84 Eric Marti, SAP and the Online Procurement Market, March 2000, Graduate School of Business 
Stanford University, Case Number: EC-5. 
   79
demand.85  i2 SCM allows organizations to design and validate the supply chain, 
understand and predict customer demand with channel partners, and forecast order 
delivery time through an efficient order fulfillment process.  
Manugistics has been a market leader of SCM software for years.  Its SCM 
products are installed in a wide base of verticals and their strength is collaboration and 
transportation management.  Manugistics SCM solutions include proven capabilities that 
address: network design and optimization, manufacturing planning and scheduling, sales 
and operations planning (S&OP), fulfillment management, collaborative VMI  , private 
trading networks, and logistics management.86  In summary, the Manugistics SCM 
solutions offer the following benefits to organizations:  real-time collaboration with the 
trading network, clearer view of the global supply chain, and optimized supply and 
demand initiatives.  
The Ariba Procurement Solution (APS) connects buyers and sellers while 
seamlessly integration with ERP and legacy systems.  Aribas two main products include: 
Ariba ORMS (Operating Resource Management System)(that) enabled employees 
throughout the organization to initiate OR purchases from their desktop computers, 
making the process highly automated(and) the Ariba Networka single global 
network serving all Ariba customers, over which they could purchase goods and services 
from any participating supplier.87  Ariba claims that these products can help 
organizations to rapidly deploy a procurement solution that has considerable ROI.  The 
Ariba spend management solutions are portrayed in Exhibit 4-8.  Since infrastructure is 
                                                
85 i2.com, Supply Chain Management, www.i2.com/solutionareas/scm/index.cfm, March 2003. 
86 Manugistics.com, Supply Chain Management, www.manugistics.com/solutions/scm.asp, April 2003. 
87 Eric Marti, SAP and the Online Procurement Market, March 2000, Graduate School of Business 
Stanford University, Case Number: EC-5, pp.11-12. 
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shared as part of an Extranet, APS allows efficient communications between buyers are 
suppliers.  Other processes streamlined by APS include contracts creation and invoice 
management.  APS delivers performance measurement using industry benchmarks.    
The Commerce One product line consists of three main components: BuySite: 
an intranet-based online procurement application (with web access for employees of 
buying organization)MarketSite: a technology platform for developing business-to-
business online marketplaces, (and) MarketSite.net: an online marketplace that 
Commerce One hosted and maintained, using its MarketSite platform.88  Furthermore, 
the Commerce One Supplier Relationship Management (SRM) software consists of the 
Commerce One Procure product.  Benefits of Commerce One Procure include reduced 
number of purchasing transactions, improved enforcements of contracts, cost savings via 
volume purchases, and utilization of an inbuilt workflow engine that manages approvals, 
orders, and shipping-related information.  This procurement software enables firms to 
create their own real-time auctioning capabilities as well.  This product integrates with 
existing CRM, ERP, and legacy systems.  A final offering of Commerce One is the 
ability of the organization to manage supplier catalogs and order information.89 
In summary, eBusiness Infrastructure such as CRM, ERP, Procurement, and SCM 
play vital roles in the pharmaceutical industry.  These components allow the firms to 
establish and maintain relationships with customers, suppliers, vendors, distributors, and 
retailers.  These automations are critical to the success of pharmaceutical companies in 
the Internet Age and subsequent case studies will reveal how various firms have 
implemented them in their eBusiness solutions.   
                                                
88 Ibid, pp. 12-13. 
89 Ariba.com, Ariba Procurement Solution, www.ariba.com/solutions/procurement_overview.cfm, April 
2003. 
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4.2. eBusiness Technical Architecture 
 
 Technically speaking, eBusiness layers interact to provide a complete solution for 
a pharmaceutical company.  Figure 4-2 depicts the technical architecture of an eBusiness 
application that contains both Infostructure and Infrastructure components.  A user 
(doctor, employee, supplier, wholesaler, and distributor) submits a transaction in the 
front-end via a browser.  This request is made to the web server, which directs the request 
to the application server.  The application server then propagates the request to the 
database, middleware, or legacy systems.  The application server or middleware can 
communicate with enterprise systems (ERP or CRM) to process the request.  The results 
are sent back to the browser in reverse order of the original request by the web server.  
This concludes a three-tier eBusiness transaction over the Internet, Intranet, or Extranet.   
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Figure 4-2  eBusiness Infostructure and Infrastructure Architecture 
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4.3. Emerging Technology  Web Services 
 
Web services are an emerging technology that can potentially disrupt technologies 
such as middleware, CORBA, and replace existing applications such as CRM, ERP, or 
EAI.  Web Services are a programming paradigm for integrating heterogeneous 
information systems, offer significant advantages over the currently available set of ad-
hoc method based on proprietary software tools(they are) based on a new set of 
standards (e.g., XML, SOAP, WSDL, UDDI)to enable data integration over corporate 
intranetsthese standards are being widely adopted in the industry as evidenced by 
Microsofts .NET initiative and SunsJ2EE.90  Web Services standards include XML 
(eXtensible Markup Language) documents for data input and output, HTTP and Message 
Orientated Middleware (MOM) for the application protocols, SOAP  a standard for 
defining how the XML documents will be exchanged, and UDDI to register the Web 
Services.91  Web services are built upon emerging standards and technologies. 
The Web Services model is based on a component-based open architecture that 
allows businesses to seamlessly perform transactions over the Internet.  According to 
Alex Nghiem, Web Services can disrupt the existing technologies by democratizing 
integration and replacing middleware / EAI.  Web services are an attempt to 
interoperability that could one day coexist with existing technologies via cleaner, human 
understandable data that provides seamless integration and adherence to standards.  This 
model has not become main stream yet, however, there is lots of hype surrounding it. 
                                                
90 Stuart Madnick and Mark Hansen, Process Aggregation using Web Services, February 2002, MIT 
Sloan. 
91 Ibid, p.19-9. 
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4.4. Conclusion 
 
 eBusiness architecture consists of components in both Infrastructure and 
Infostructure layers.  These products include application servers, web servers, databases, 
middleware, CRM, ERP, SCM, and procurement software developed by leading vendors.   
It is appropriate to begin evaluating real-world business cases in the 
pharmaceutical industry.  We begin with the eProcurement phase, followed by eSales, 
and concluding with eSupplyChain.  Some case studies are published and available to the 
public, while others that were interviewed desired to remain anonymous.  The quality and 
information provided in each case is equally pertinent for this research.   
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4.5. Exhibits 
 
Exhibit 4-1  SunOne Architecture92 
 
 
 
 
Exhibit 4-2  Oracle 9i Database Architecture93 
 
                                                
92 Sun.com, Sun Open Net Environment (Sun ONE), April 2003, wwws.sun.com/software/sunone/. 
93 Oracle.com, Oracle 9i, Database Features, April 2003, 
www.oracle.com/ip/deploy/database/oracle9i/index.html?oracle9idb_features2.html. 
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Exhibit 4-3  BEA Tuxedo Architecture94 
 
 
Exhibit 4-4  BEA MessageQ API95 
                                                
94 BEA.com, Introducing BEA Tuxedo, e-docs.bea.com/tuxedo/tux81/overview/overviea.htm. 
95 BEA.com, Products: MessageQ, April 2003, 
www.bea.com/framework.jsp?CNT=datasheet.htm&FP=/content/products/messageq/. 
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Exhibit 4-5  Web Server Architecture96  
 
 
Exhibit 4-6  Siebel CRM Products for Sales & Analytics97 
                                                
96 Sun.com, Phil Chang, Inside the Java Web Server, August, 1997, 
java.sun.com/features/1997/aug/jws1.html. 
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Exhibit 4-7  PeopleSoft CRM Products for Advisor98  
 
 
 
Exhibit 4-8  Ariba Spend Management solutions99 
 
                                                                                                                                            
97 Siebel.com, Sales: Product Description, April 2003, 
www.siebel.com/products/sales/siebel_sales/product_module_desc.shtm. 
98 PeopleSoft.com, Product Module: Advisor, April 2003, 
www.peoplesoft.com/corp/en/products/line/crm/advisor/features.jsp. 
99 Ariba.com, Ariba Procurement Solution, March 2003, 
www.ariba.com/solutions/procurement_overview.cfm. 
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Exhibit 4-9  PeopleSoft, Extending the Enterprise Information System100 
                                                
100 Eric Marti, Diagram adopted from Stanford University Graduate Business School (March 2002, Case # 
EC-5), The Economist, 6/26/99. 
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5.0. Chapter Five:  eProcurement Case Studies 
 eProcurement is an important component of eBusiness and pharmaceutical 
companies utilize this phase to connect with suppliers to buy products that they can then 
use for manufacturing drugs and healthcare products.  The following case studies 
evaluate eProcurement and related eBusiness technologies.   
5.1. Case Study One: eProcurement at Novartis 
 
Since 2001, Novartis has implemented a global eProcurement systems based on 
the Ariba platform that covered the US, Europe, and Japan.  The strategic discipline 
behind this project was to monitor direct and indirect spending on purchases that reached 
nearly $8.7 billion annually.  Most of this spending was based on eCatalogs that 
contained nearly 700,000 items supplied by hundreds of suppliers worldwide.  
Implementing an eProcurement system was new to most firms in the pharmaceutical 
industry, and this project allowed the Novartis to put a purchasing process in place.  
Novartis claims to be the first pharmaceutical company in the world to implement e-
procurement on a global basis and with all spend categories in scope.101  Thus, Novartis 
was one of the early adopters that implemented a global eProcurement solution for 
conducting eBusiness with suppliers.   
The eProcurement project offered several major benefits to Novartis.  Although, 
the pharmaceutical firm incurred significant cost on its global eProcurement project, it 
was worth the investment.  The total amount spent by Novartis was nearly $15 million, 
however, it was expecting a cost saving of annual $220 million, annually on both direct 
                                                
101 Andrew McAfee, eBusiness at Novartis, Harvard Business School, August 2001, p.11. 
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and indirect spending costs.  Another benefit of the eProcurement project was that it 
forced suppliers to standardize their catalogs in the correct format to integrate with this 
new system at Novartis.  Finally, eProcurement allowed Novartis to benchmark prices set 
forth by suppliers, because it now had an IT system in place that offered such 
functionality.  Hence, eProcurement offered Novartis many benefits critical to its success 
in the pharmaceutical industry.  
5.2. Case Study Two: eProcurement at Pharma2 
 
Pharma2 is one of the leading manufacturers of contacts lens in the Europe.  This 
pharmaceutical company has invested heavily in IT infrastructure and focused most of its 
initiatives on eSales and eMarketing.  More recently, Pharma2 is in the process of 
implementing a mySAP eProcurement platform to improve relationship with suppliers. 
Pharma2 has launched a major initiative around developing an eProcurement 
platform in Europe.  The firm has realized it has struggled in the past from consolidating 
information related to suppliers and vendors.  The firm has partnered with a leading 
systems integrator based out of the US and is currently implementing an SAP-based 
procurement system that can deliver information related to suppliers, purchasing, and 
products.  The new system will deliver functionality such as financials, purchasing, sales, 
and distribution.  This new system will replace the existing IBM AS/400 manufacturing, 
ordering, and distribution system.  Thus, Pharma2 is in the process of improving their 
eProcurement platform being delivered by SAP. 
Pharma2 is currently lacking in the eProcurement space for their US operations.  
The firm has long-term plans for moving to a package-based solution, however, currently 
such information is stored in excel spreadsheets or other non-formal electronic media.  
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On a given day, according to Catherine, a senior manager involved in this new initiative, 
we cannot tell you how much we have spent and how many suppliers we haveall this 
information is stored in excel spreadsheets.102  This is critical to Pharma2s business and 
will need to be rectified as other pharmaceutical companies are forging ahead with 
eProcurement initiatives in the US. 
5.3. Case Study Three: eProcurement at Pharma6 
 
Pharma6 is one of the largest pharmaceutical company in the world and it is 
composed of the following business units:  health care, consumer health, and animal 
health.  Pharma6 develops healthcare and consumer products that are available in more 
than 150 countries.  This organization has been at the forefront of implementing global 
eSales, eMarketing, and eProcurement solutions. 
In 2000, Pharma6 announced to standardize on the Ariba B2B eCommerce 
Platform to streamline their global eProcurement initiatives.  The Ariba Buyer 
application was being used to develop an internal procurement system that allows refined 
management of operating supplies and services in corporate and research facilities. The 
Ariba Buyer allowed Pharma6 to consolidate 30,000 suppliers and has enabled global 
purchasing and direct spending capabilities from the desktop.  Other Ariba products 
being implemented include Ariba Buyer, Ariba Sourcing, and Ariba Marketplace, 
all of which have improved business processes and relationships with suppliers and other 
business partners.  The functionality offered by the Ariba products include: seamless 
collaboration between buyers and suppliers, catalog services, and transaction 
management. 
                                                
102 Interview: Catherine.  
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Pharma6 has implemented an eProcurement system that was originally based on 
Ariba.  While discussing eProcurement at Pharma6, David (senior manager, 
Procurement), revealed that the original Ariba system integrated with general ledger and 
financial systems in the backend enterprise systems.  Pharma6 has not standardized on 
any ERP systems as it continues to acquire smaller pharmaceutical companies and does 
not want to invest heavily in such software.  Inventory orders at the manufacturing flow 
through the Ariba procurement system to the suppliers.  The Ariba e-Invoice and e-
Sourcing packages are used by Pharma6 business units at a global scale.  Pharma6 has 
developed a computer maintenance management system (CMMS) for its procurement 
systems to interface with suppliers.  
According to David, Pharma6 has used auctions at both large and small scales for 
eProcurement.  FreeMarkets Online has been a reliable source that Pharma6 has used to 
buy products online and is usually related to large events.  For smaller purchases, 
Pharma6 has relied on small auctions setup by wholesalers and suppliers to buy products 
required for manufacturing drugs.  eProcurement systems are used to buy raw and 
package materials, in addition to indirect materials (non-cost of goods) products.  In the 
future, Pharma6 is considering developing its own eBusiness tools for eProcurement, 
which would provide self-service type of auctions with suppliers of their own choice.  
5.4. Case Study Four: eProcurement at AstraZeneca 
 
Based out of the UK, AstraZeneca is one of the world largest research-based 
pharmaceutical firms that implemented the mySAP E-Procurement in 2002.  AstraZeneca 
spends nearly $8 million daily on R&D efforts and has delivered a variety of healthcare 
products using innovative techniques.   
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Prior to implementing the B2B SAP E-Procurement system, AstraZeneca 
employees manually placed orders for supplies.  The disadvantages of this approach 
included long ordering cycles, redundant data entry, and inefficient search capabilities of 
products and suppliers.  In a three-month development effort, the core product of mySAP 
Enterprise Buyer was installed.  AstraZeneca selected the mySAP E-Procurement 
platform because of existing implementations of SAP ERP products, existing 
implementation partnership with SAP, and the ability to e their procurement process 
from the existing pen-based system.  
There were numerous benefits of the new mySAP E-Procurement effort at 
AstraZeneca.  First of all, the interface was extremely user-friendly.  Secondly, using the 
Internet-based procurement business process templates allowed AstraZeneca to rapidly 
e their procurement process.  The new procurement system eliminated the need to 
verify and validate purchase ordering documents.  Historic data related to orders was now 
available in a repository.  Finally, this system allowed AstraZeneca to reduce cost related 
to so-called maverick or spontaneous buying, because the firm could not analyze trends 
and forecast orders versus ordering each time products were needed from suppliers.   
Moving forward, AstraZeneca, is looking at additional SAP software.  In order to 
carefully analyze forecasting and buying in procurement, this firm is looking at mySAP 
Business Intelligence software package.  Moreover, AstraZeneca is planning on 
developing an automated and integrated document flow system using XML.  Hence, 
AstraZeneca has rapidly transformed its primitive procurement processed to an electronic 
package solution that has increased efficiency, productivity, and cost savings. 
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5.5. Conclusion 
 
 In review, eProcurement systems have been developed in several major 
pharmaceutical companies worldwide.  The original systems were legacy mainframe, 
AS/400, electronic spreadsheets, or even pen-based.  The new systems include mySAP E-
Procurement, Ariba Buyer, Ariba Sourcing, and Ariba Marketplace.  Although, some of 
these pharmaceutical companies have used online auctioning websites such as Free 
Markets Online for large events, many are using Ariba software for smaller auctions. 
 The companies discussed in the eProcurement case studies have implemented 
various eBusiness technologies and pursued several trends.  Novartis has successfully 
developed an Ariba-based procurement system for consolidating global operations.  The 
eProcurement solution at Novartis has been rather expensive, but the overall cost being 
saved is phenomenal.  Pharma2 is in the process implementing an eProcurement solution 
in Europe using mySAP Procurement that will be replacing traditional activities such as 
storing critical procurement data in electronic spreadsheets.  Pharma6 has successfully 
implemented an Ariba-based system using several buying and purchasing modules.  This 
firm has also used Ariba for small auction events.  In several months, AstraZeneca has 
developed and eProcurement system using mySAP E-Procurement software package.  
This system has saved this pharmaceutical company extensive cost and fully optimized 
supply chain activities across the globe.  Hence, eProcurement using several platforms 
has been successfully implemented in pharmaceutical companies analyzed in this chapter. 
 After discussing eProcurement, the next phase of interest is eSales.  The following 
chapter consists of case studies that discuss how eBusiness and related technologies are 
impacting eSales in pharmaceutical companies. 
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6.0. Chapter Six:  eSales Case Studies 
 eSales is one of the most important constituents of eBusiness.  eSales have been 
implemented across pharmaceutical companies in both custom and packaged solutions.  
eSales allows business partners to place orders online 24 / 7 / 365.  This is an important 
reality of the Information Age and pharmaceuticals IT strategies are being modified to 
accommodate this certainty.  The following case studies have been performed on firms 
throughout the world to determine what technologies and trends are emerging in the 
eSales phase of eBusiness in the pharmaceutical industry.     
6.1. Case Study One: eSales at Novartis 
 
Novartis is the fourth largest pharmaceutical company in the world and this firm 
has established an extremely strong infrastructure for eBusiness and IT.  Novartis, based 
out of Switzerland, has adopted various eBusiness models to enter the digital age.  These 
decisions have been made at the senior executive level and this sponsorship has been a 
key to their success.  Novartis has used eBusiness in all aspects of their drug development, 
marketing, sales, learning, supply chain, and procurement process.   
In March 2000, Novartis partnered with iPhysicianNet to develop an eSales 
initiative.  This firm specialized in providing Internet video conferencing that could 
connect doctors and pharmaceutical firms.  To complement this, Novartis established 
eReps who began to compete with the existing field representatives.  It is reported that 
eReps were fundamentally more productive than the field representatives in terms of 
numbers of calls made, delivering product presentations, selling the core marketing 
message, number of physicians reached, and attaining market share for new products.  To 
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complement eSales, Novartis used eBusiness for additional purposes.  Selling products 
that were coming off-patent or already off-patent using the Internet was a successful 
strategy.  This allowed additional revenue stream from products that were declining in 
sales at the local pharmacies and other retail locations.   
In summary, Novartis has successfully implemented eBusiness in all processes of 
their business.  The firm created an e-Trial portal to conduct recruit drug candidates 
online with an incentive to reduce cost and time in clinical trial phase.  Since the mid-90s, 
Novartis has created globally brand websites for marketing their products in addition to 
websites for common diseases as well as those targeting certain age groups such as the 
elderly.  Novartis partnered with a high-tech video conferencing firm to develop an 
eDetailing offering.  To supplement this, Novartis established several eSales channels to 
sell off-patent drugs online for additional revenue streams.  Novartis partnered with 
Harvard University to develop eLearning initiatives for partnering physicians who were 
interested in continuing education.  In the US, Novartis established a substantial network 
that allowed partners such as wholesalers and distributors to track their orders.  The 
purpose of this project was to successfully implement an eSupplyChain application.  
Hence, Novartis can be considered a trend-setter in implementing eBusiness solutions in 
the pharmaceutical industry and their size and the time since which they have been 
involved with e initiatives supports this claim. 
6.2. Case Study Two: eSales at Pharma1 
 
Pharma1 is a leading manufacturer of contacts lens in the United States with 
additional operations in Asia, Europe, Middle East, and Latin America, and this billion 
dollar company has implemented eBusiness technologies in all facets of their business 
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processes.  The firm has not yet implemented an eProcurement strategy.  The firm has 
developed a strong online brand for their products.  Additionally, eLearning at Pharma1 
is based on offering web-based continuing education programs to doctors.  Finally, 
Pharma1 has developed a B2B website where business partners can perform activities 
related to eSales and eSupplyChain.   
Pharma1 developed their first eCommerce initiative in 1997 based on a Java 
Applet web application that faced limited user adoption based due to user connectivity 
bandwidth and performance issues.  Since then, Pharma1 has established substantial 
eBusiness initiatives for eSales.   
In 2000, Pharma1 launched a high-performing multi-user B2B website where 
business partners such as retailers, distributors, and doctors can purchase contact lens.  
The technical architecture of this exchange is depicted in Figure 6-1.  This website is 
built on the J2EE platform.  Most of the hardware is manufactured by Sun Microsystems.  
The development server and production servers both run the UNIX-based Sun Solaris or 
HP-UX operating systems.  The web server is the high-performing Sun Microsystems 
iPlanet Web Server.  The application server is the world-famous BEA WebLogic.  Oracle 
9i is the underlying database system for this website.  The client-interface of this website 
is developed using Java Server Pages and Java Servlets.  Integration with the backend 
systems is performed using the component-based Enterprise Java Beans.  This web 
system integrates with an IBM AS/400 mid-range system that contains both ordering, 
manufacturing, and distribution capabilities.  In its first year, this website sold nearly 5% 
of the annual sales of this pharmaceutical company and that number is in the 10s of 
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millions of dollars.  Hence, the technical architecture established by Pharma1 is quite 
leading-edge and robust.   
Since Pharma1 products have a large variety of prescription-related data 
associated with them, the firm saw the need to develop the front-end of their eBusiness 
applications using a custom software solution instead of a packaged one.  In the contact 
lens industry, ordering the products requires the input of information such as base curve, 
prescription number, color, and product.  Numerous combination of these variables 
resulted in the need to build a custom front-end for this eBusiness application. 
For security reasons, Pharma1 relied heavily on the EDI technology.  The firm 
felt that revealing the IBM AS/400 backend system to the web application would not be a 
feasible option, therefore all web transactions were converted to EDI formats that were 
then placed into a special directory on the UNIX server to be processed in batch every 
half hour.  This allowed all transactions to be recorded on the web application in the 
Oracle 9i database, and then each transaction for further processing by the IBM AS/400 
programs in the backend to initiate ordering or distribution calls.  Finally, direct calls 
could be made to the IBM AS/400 when gathering read-only information such as order 
status or related tracking information.  It is evident that EDI technologies are still utilized 
for performing eBusiness transactions because they are proven and secure.   
In his research on eCommerce, Kalanidhi states that the Internet is enabling 
businesses to experiment with new business models.103  Pharma1 has done just that with 
mBusiness initiatives in Japan.  According to Randy, Pharma1 has invested in mBusiness 
in their Japanese operations using a B2C model.  Customers of Pharma1, for example, in 
                                                
103 Sanjeev Kalanidhi, Thesis: E-Business Strategy:  An Industry Clockspeed Perspective, 2000, p. 30, 
MIT Thesis, MIT Engineering Systems Division. 
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Japan can receive an SMS notification on their cell phone that the eye doctor has filled 
their electronic prescription.  The customer can pay for their supply of contact lens using 
a credit card, over the cell phone.  This system is integrated with the Japanese subway 
system and when the payment is made, the customer can select which subway stop to 
have their package delivered to.  Hence, upon leaving work or any other location, the 
customer can stop at the designated booth at the subway station to pick up their order.  
Pharma1s parent company has implemented several eBusiness solutions in other 
companies.  CRM technologies at other Pharma1 sister-companies include E.piphany.  
According to David (eBusiness Manager), the corporate headquarter of Pharma1 has 
standardized on two main ERP packages: SAP and J.D. Edwards.  Application servers 
being used in other subsidiary companies include ATG Dynamo and SunOne Application 
Server.104  Finally, middleware technologies at various companies include Tibco and 
BEA Tuxedo. 
Thus, we see that Pharma1 has established significant e-Initiatives around their 
business in the eye care industry in the US.  They are in the process of migrating their 
IBM AS/400-based manufacturing and distribution system to an SAP-based financials, 
sales, and distribution platform.   The firm has used the Internet since the mid-90s to 
establish brand recognition, and in 2000 developed a world-famous product-based 
website for marketing purposes.  For eSales, Pharma1 has developed a leading-edge 
website using latest J2EE technologies with integration with AS/400, Oracle 9i on the 
UNIX platform to allow business partners to place order 34/7/365.    
                                                
104 Interview: David. 
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Figure 6-1  Technical Architecture of Pharma1 B2B website 
 
6.3. Case Study Three: eSales at Pharma2 
 
Pharma2 is one of the leading manufacturers of contacts lens in the Europe.  
Pharma2 has developed a multi-lingual website for Germany, France, and the UK where 
business partners can perform eSales and eSupplyChain ventures.   
Pharma2 has developed a B2B and B2C online order website for doctors, patients, 
retailers, distributors, and wholesalers in Europe.  Figure 6-2 depicts the technical 
architecture of Pharma2s eSales implementation.  In terms of the Infostructure, this 
website is deployed on the Netscape Web Server, NetDynamics Application Server, and 
Oracle 9i Database.  In terms of the Infrastructure, the regional enterprise systems include 
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an IBM AS/400 or J.D. Edwards ordering and distribution systems.  Customer service 
representatives can take orders directly on the AS/400 or on the web application.  The 
EDI interface is used to convert web orders into the AS/400 system.  Infostructure and 
Infrastructure components reside on a Sun Solaris UNIX operating system, and backend 
integration is possible due to EJB components deployed in the application server.   
Additional features of this website include globalization and direct patient 
ordering.  This site offers multi-lingual capabilities in that it can be rendered in multiple 
languages (English, French, and German).  This capability was possible due to the Java 
Internationalization (I18N) feature.  Additionally, patients can dial up and place orders 
for contacts and even authorize debit from their check cards.  This application is directly 
integrated to European banks, so that withdrawals are real-time.   
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Figure 6-2  Technical Architecture of Pharma2 B2B and B2C website 
   102
6.4. Case Study Four: eSales at Pharma3 
 
Pharma3 is one of the leading manufacturer of spectacle lens in the US.  This 
organization developed a pure eBusiness strategy enabling direct integration from the 
Internet to manufacturing to distribution.  This B2B website enabled eye care physicians, 
sales representatives, and customer service representatives to place orders for spectacles.   
The technical architecture for Pharma3s B2B website was leading-edge with a 
highly innovating approach to eBusiness.  First of all, this website required no need for 
human intervention after the initial order placement.    The Infostructure consisted of an 
Oracle 9i database, Netscape Web Server, and a NetDynamics Application Server.  The 
backend enterprise system was an SAP Manufacturing system that connected directly 
with a robotics-based spectacle lens manufacturing plant.  The front-end of this 
application was developed using a NetDynamics-proprietary interface that rendered 
HTML pages using Java and an event-driven model.  The backend integration was 
delivering using the EJBs and the Java Connector Architecture that integrate with SAP 
Business Application Programming Interfaces (BAPI) to the manufacturing system.  
After successful manufacturing, the product would be send directly to an automated 
distribution system also based on the SAP product line.  The eBusiness application was 
available 24 / 7 / 365 and was developed using custom software, because of the high 
requirements for parametric data to construct the spectacle lens.  Hence, Pharma3 
integrated a Java-based web application with an automated SAP manufacturing system to 
deliver an eSales application for their spectacle lens products. 
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6.5. Case Study Five: eSales at Pharma4 
 
 Pharma4 is one the largest pharmaceutical company in the world with products 
health, consumer, and animal products begin sold in more than 150 countries.  This 
multi-billion dollars company spends millions of dollars daily on R&D efforts and owns 
manufacturing facilities in more than 50 countries.  
Although eSales at Pharma4 have continued to use traditional technologies while 
dealing with business partners, there are future plans of web portals.  While discussing 
their B2B initiatives, Shane (senior manager, B2B eCommerce), mentioned that Pharma4 
has traditionally used EDI to exchange ordering data with business partners.  He believes 
EDI will not go away and dominates their ordering transactions with 86% of revenue in 
his group.  Additionally, all of Pharma4s top 50 business partners use EDI to exchange 
their data for ordering.  The sales of products cover both direct and indirect sales.   
 Pharma4 has a significant strategy for moving to the Internet for eSales initiatives 
in the future.  The firm is currently piloting a B2B customer portal.  The move to the 
Internet is motivated by the following factors:   
1. Cost reduction. 
2. Security. 
3. Order management. 
Web systems save cost, because EDI investments and maintenance can be high, 
especially for large systems like the one at Pharma4.  Web systems are secure using 
firewall technologies and encrypting data with SSL.  Orders placed on the Internet can be 
tracked a lot easier by business partners, who no longer need to call and get assistance 
after, for example, an EDI upload.   
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Shane believes that Pharma4 has invested heavily in the EDI infrastructure and 
the maintenance continues on it.  He feels that moving to the Internet with clean data 
while designing a web portal will offer Pharma4 a more flexible ordering system in 
which users will be able to place orders using typical Internet scenarios such as shopping 
cart applications and order status checking.   Defining the data will be an important factor 
for the success of the web portal.  Pharma4 faces the challenge of consolidating data 
definition with business partners so that correct products are ordered.  XML will be used 
for definition of data standards.   
 Advantages of the online system include order tracking that can be used for 
forecasting sales and increased sales because the system will be available 24 / 7 / 365 
versus customer service representatives who have finite hours of availability during the 
week.  Pharma4 is evaluating bar code technology as mandated by the uniform code 
council (UCC).   Basically bar code numbers are assigned by the UCC and stored in a 
registry in cyberspace to create global standards for ordering using this technology.  
Pharma4 is researching radio frequency identification (RFID), a standard being 
developed at MIT, for uses such as ordering.   Pharma4 plans on setting up a public portal 
that can allow business partners to scan products labeled with bar codes or RFIDs over 
the Internet to allow partners to fill their stock and inventory of Pharma4 products.   
 Pharma4 pharmaceutical and consumers groups are both using the same 
technologies for their eSales.  Their support is common and their goal is to seek 
alignment with their customers.  Pharmaceutical sales are rigid because of a smaller 
client base worth billions, as opposed to consumer sales which are more dynamic with a 
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much larger client base worth only millions.  Pharma4 has standardized on both IT 
support and EDI for both consumers and pharmaceutical groups.  
6.6. Case Study Six: eSales at Roche105 
 
 In the summer of 2001, Shanghai Roche Pharmaceuticals announced that it will 
build a sales and marketing platform using Siebels eBusiness platform, ePharma.  
Shanghai Roche is the biggest pharmaceutical company in China where it serves drug 
stores and hospitals in almost fifty cities.  The ePharma is a single information system 
that provides multi-channel capabilities to sales and marketing representatives.  This 
platform allows Roche to promote new drugs as well and monitor sales and forecast 
future demand.   
 Prior to implementing Siebel ePharma, Roche was using a paper-based system for 
sales and marketing data across numerous departments.  The new system will provide 
Roche a centralized data repository for sales and marketing data that could be accessed in 
real-time across the organization in China.  The sales data could be used by the sales 
representatives who can then analyze customer ordering data and trends before making a 
sales call.  This enables streamlining of the sales cycle at Shanghai Roche.  This data will 
also allow the firm to measure performance and sales data at a national scale, something 
that was impossible in the past.  Hence, implementing Seibel ePharma at Shanghai Roche 
is a major improvement of past IT systems. 
 According to Michael Xu (sales development manager, Shanghai Roche), "Siebel 
ePharma will bring us closer to our customers and enhance our relationships with them 
                                                
105 Siebel.com, Press Release: Shanghai Roche Standardizes on Siebel eBusiness Platform, July 2, 2001, 
www.siebel.com/about/news_events/press_releases/2001/010702_shanghai.shtm. 
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across all points of contact.106  Thus, Siebel ePharma delivers CRM functionality to 
improve relations with business partners in the Chinese pharmaceutical industry.  
Furthermore, the ePharma system is flexible and scalable to meet Roches needs in their 
industry.  In conclusion, implementing the ePharma system at Roche has been a success 
for this pharmaceutical company in terms of sales and marketing.  
6.7. Case Study Seven: eSales at Boehringer Ingelheim107 
 
 Based out of Germany, Boehringer Ingelheim, is one of the top 20 largest 
pharmaceutical companies in the world that in 2002 standardized on the Siebel eBusiness 
platform with the ePharma 7-a portfolio.  This global system was deployed to address the 
needs for sales representatives in improving relationship with physicians.  Typically, 
physicians and doctors were responsible for prescribing Ingelheim products to patients 
who then bought them from pharmacies.  This eSales system also evaluated physician 
prescription habits.   
 Historically, data related to physician activity was stored in intra-business unit 
systems that could not be shared by sales representative in other practices of Boehringer 
Ingelheim.  The new Siebel ePharma 7-a system integrated seamlessly with other sales 
and marketing systems and this centralized data repository could be accessed real-time by 
whoever found it valuable.  Furthermore, sales professionals could use this system to plan 
sales call with physicians while managing their sales territories.  Hence, the new Siebel 
ePharma system at Boehringer Ingelheim improved relationships between sales and 
marketing and their most important customers  the physicians.   
                                                
106 Ibid. 
107 Siebel.com, Press Release: Boehringer Ingelheim Standardizes on Siebel eBusiness Applications 
Worldwide, Feb. 12, 2002, 
www.siebel.com/about/news_events/press_releases/2002/020212_boehringer.shtm. 
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 According to Dr. Bert Tjeenk-Willink (corporate marketing director, Boehringer 
Ingelheim) the new system enabled them to "streamline the day-to-day management of 
the sales process and maximize efficiency  the extensive tailored functionality of 
Siebel ePharma 7-a made it the ideal choice for this 'best practice' strategy.108  Hence, 
Siebel ePharma 7-a improved the processes related to enhancing sales with physicians 
based on historic prescription data and sales patterns of physicians in a real-time fashion.    
6.8. Conclusion 
 
 After analyzing eSales case studies of in the pharmaceutical industry, it is evident 
that numerous eBusiness technologies and models are being pursued.  Most of the 
eBusiness models being pursued are B2B, while there are isolated instances of B2C and 
mBusiness abroad.  Many eSales implementations are being developed on J2EE-based 
application servers that integrate with legacy or mid-range backend systems.  Several 
firms have used the Siebel eSales and eMarketing custom software platform for 
eBusiness to automate this phase in their organization.   
 The pharmaceutical companies discussed in this chapter have successfully 
implemented eBusiness solutions for the eSales phase in their value chain.  Novartis, has 
used the iPhysicianNet for selling products to business partners.  Pharma2 has developed 
a B2B website based on the J2EE platform for selling their products to business partners.  
This company is using EDI technologies as well.  Pharma2 has developed an 
Internationalized B2B website in Europe based on the proprietary NetDynamics platform 
that integrates with IBM AS/400 enterprise distribution and manufacturing systems.  
Pharma3 has developed an innovative NetDynamics-based B2B website that integrates 
                                                
108 Ibid. 
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directly with an SAP manufacturing system that is processed by robotics.  Pharma4 is in 
the process of migrating from EDI technologies to web portals based o n the Java 
platform and is also considering using late auto-id technologies such as RFID.  Roche has 
successfully implemented Siebel sales and marketing application in China to improve 
relationships with doctors.  Finally, Boehringer Ingelheim has built a sales application 
using Siebel e-Pharma 7 platform to optimize relationships with doctors and other 
business partners.  Hence, diverse eSales solutions have been developed at 
pharmaceutical companies across the globe. 
 After discussing eSales, it is now time for our final case study segment that 
evaluates eSupplyChain.  This process is linked to eProcurement and is very critical to 
performing successful eBusiness in the pharmaceutical industry.  
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7.0. Chapter Seven:  eSupplyChain Case Studies 
 eSupplyChain is one of the most important components of eBusiness and 
pharmaceuticals utilize this phase to connect with suppliers, vendors, distributors, 
wholesalers, doctors, physicians, and retailers to deliver drugs and other products across 
the value chain.  Simple truth is that the more efficient the supply chain, the more 
productive and successful a firm is in delivering products to the market. 
7.1. Case Study One: eSupplyChain at Novartis 
 
Novartis established eSupply chain activities in the United States under a 
proprietary Extranet called Novartis customer connection (NCC).  Basically, business 
partners such as suppliers, distributors, retailers, and physicians who are interested in 
accessing data related to product delivery are authorized to be part of this Extranet system.  
This in-house project, considered one of the earlier for supply chain management, was 
aimed at improving relationship with business partners such as wholesalers and 
distributors.  The website offered partners to track orders online.  The main purpose was 
to move away from traditional method of calling to customer service representatives to 
get order tracking information.  Novartis does not consider eSupplyChain to be a strategic 
activity in their formal work stream and has not implemented this in Europe thus far.  
7.2. Study Two: eSupplyChain at Pharma1 
 
Pharma1 is a leading manufacturer of contacts lens in the United States revenues 
of more than a billion dollars and global operations.  Pharma1 has developed a B2B 
website where business partners can perform activities related to eSupplyChain 
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Pharma1s B2B website offers critical supply chain information to business 
partners.  Wholesalers, distributors, retailers, and doctors can log in to the website to 
check order status information.  According to Director of eBusiness at Pharma1, Randy, 
the firm is now in the process of delivering this information 24 / 7 / 365 where the users 
do not need a customer service representative to provide them this data.109  This 
encompasses additional functionality such as the partners being able to check account 
balance with Pharma1 on weekends, days on which currently no customer service 
representatives are available by phone.  The website also contains links to FedEx for 
order tracking, once it has left the distribution facilities at Pharma1.  Pharma1s website 
offers both eSales and eSupplyChain capabilities that allow business partners to track 
orders online.   
7.3. Case Study Three: eSupplyChain at Bristol-Myers 
Squibb110 
 
 Bristol-Myers Squibb is a $20 billion company that produces a wide variety of 
drugs and consumer products that treat serious illnesses.  This company has been around 
since the mid-19th century and operates globally. 
In 2002, Bristol-Myers Squibb implemented an i2 SCM system based on the i2 
Supply Chain Planner product line.  Fluctuating demands and improving operations are 
common issues in the pharmaceutical industry that were also faced by Bristol-Myers 
Squibb.  After a recent acquisition, this pharmaceutical company was faced with the 
                                                
109 Interview: Randy. 
110 i2.com, Success Story: Reducing Planning Cycle Time at Bristol-Myers Squibb, March 2003, 
w.i2.com/assets/pdf/3F05754C-1786-4D82-89CC04D7BCB3CD42.pdf. 
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challenge of optimizing networks across various business units.  Bristol-Myers Squibb 
decided to automate their SCM system using the i2 Supply Chain Planner.   
 The motivations for implementing i2 Supply Chain Planner were to reduce cost 
by lowering inventory and decreasing the supply chain planning cycle times.  Benefits of 
the i2 Supply Chain Planner include: 
1. Collaborate on demand across business units. 
2. Optimization of Manufacturing supply chain. 
3. Reduce Transportation costs. 
4. Standardize a consensus-based forecasting model. 
Perhaps the biggest benefit of the i2 Supply Chain Planner product line to Bristol-
Myers Squibb was that the company could consolidate the manufacturing and distribution 
networks as one supply chain network based on an Extranet-enabled architecture. 
 There were many benefits in implementing i2 at Bristol-Myers Squibb.  The 
supply chain planning cycle was reduced from 2-3 months to a few hours.  The amount of 
effort was minimized and reducing the inventory with the new system allowed for better 
results in other efforts as well.  Using i2 Supply Chain Planner, Bristol-Myers Squibb 
was able to plan on a weekly basis to balance the supply and demand across their value 
chain.  The i2 implementation also offered Intra-enterprise collaboration for supply chain 
management in that real-time data was accessible to all business units across this global 
pharmaceutical manufacturing and distribution groups.  Another shortfall before the i2 
implementation was that supply chain data was not available real-time and nor was it 
accurate, since it was stored in electronic spreadsheets that were hard to manage and 
consolidate across different plants.  Better collaboration led to improved communications 
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amongst disparate groups that in the past did not speak very often, although they were on 
the same product value chain.   
7.4. Case Study Four: eSupplyChain at Pfizer111 
 
Pfizer is one of the largest and most famous pharmaceutical companies in the 
world that products drugs and products sold in more than 150 countries.  With revenues 
of more than $30 billion, this pharmaceutical company relies heavily on IT for supply 
chain initiatives.  Pfizer made the decision to develop a global system was to integrate the 
supply chain amongst its three main focuses:  pharmaceuticals, consumer, and animal.  In 
the spring of 2002, Pfizer announced that it has implemented a Manugistics-based 
fulfillment management solution.   
 There are many advantages of the new Manugistics supply chain management 
systems developed at Pfizer.  Benefits include the following:   
1. Efficient inventory management. 
2. Improved customer service. 
3. Reduction of certain inventory levels. 
4. Reduction of logistics costs. 
5. Improved manufacturing capabilities. 
These are all important rewards of implementing a global supply chain management 
system.  Many of these benefits can be attributed to the Manugistics software.  First of all, 
the Manugistics solution for supply chain has seamlessly integrated with Pfizers order 
entry system and material resource planning system, that are functional in more than 50 
manufacturing sites worldwide.  Increased visibility of the supply chain allows better 
                                                
111 Manugistics.com, Press Release: Pfizer Selects Manugistics Global Fulfillment Management System, 
March 13, 2002, www.manugistics.com/news/detail.asp?id=228. 
   113
management of the supply chain and also allows tracking of material and supplies so that 
improved relationships could be accomplished with customers.  Finally, Pfizer sees this 
system in assisting in the move from a supply-to-order system to a supply chain 
replacement system of used and out-of-date inventory.  Thus, implementing a 
Manugistics SCM system has allowed Pfizer to improve its inventory management, 
customer service, and integrations with manufacturing systems.  
7.5. Case Study Five: eSupplyChain at AstraZeneca112 
 
AstraZeneca is one of the top 20 pharmaceutical companies in the world and one 
of the top 5 in terms of R&D.  In 2001, AstraZeneca developed a Manugistics 
NETWORK supply chain management system to create a receptive and efficient 
supply chain.  The two salient reasons for this implementation were to reduce cost 
(related to almost expired inventory) and to reduce the total finished goods inventory.   
Historically, AstraZeneca supply chain management system consisted of several 
in-house systems integrated with a legacy automated system in the US business units.  
This system features inventory and capacity planning.  The new system that was based on 
a Manugistics NETWORK enabled AstraZeneca with the following advantages: 
1. Improve the existing fulfillment network. 
2. Develop new distribution centers. 
3. Model alternative supply chain scenarios. 
4. Improved customer service. 
                                                
112 Manugistics.com, Press Release: AstraZeneca Implementing Broad Suite of Manugistics Supply Chain 
Solutions, November 6, 2001, www.manugistics.com/news/detail.asp?id=192. 
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One can consider the Manugistics NETWORK to be an evolution of Extranet SCM 
system developed in the mid-90s.  Basically, all business partners and internal staff are 
authorized to use this system for performing supply chain monitoring activities.  All the 
aforementioned advantages were made possible using web-based analytics and 
forecasting tools that are part of the Manugistics suite of supply chain management 
products.  According to Grace DiCecco (project manager of operations capability 
planning at AstraZeneca), "by using Manugistics solutions to improve the visibility and 
effectiveness of our fulfillment network, we expect to enhance our commitment to 
customer service."113  Since the new system provided a better view of the entire supply 
chain, customer service was enhanced as well.  Additional benefits of the new system 
consist of inventory-optimization while considering product shelf-life.  Also, distribution 
of products to business partners such as wholesalers was another benefit of the 
Manugistics NETWORK solution at AstraZeneca.  A final and perhaps the most 
important benefit is the ability to effectively manage the supply chain as new 
AstraZeneca products are launched in the market with important considerations of 
customer demand in the industry. 
7.6. Conclusion 
 
 In terms of implementing eSupplyChain solutions, firms in these case studies 
show a mix of custom software and packaged solutions.  Manugistics seems to be the 
dominant SCM software in the industry, although firms have developed custom software 
on the J2EE platform that integrates with backend manufacturing and distribution 
                                                
113 Ibid. 
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systems to allow business partners to track orders and check other order status 
information.   
 The pharmaceutical companies analyzed in this case have diversely implemented 
eSupplyChain solutions.  Novartis is considered to be on the leading companies in 
implementing the proprietary Extranet SCM, Novartis Customer Connection, for business 
partners.  Pharma2 implemented a custom eSupplyChain solution using the J2EE 
platform to allow business partners to track orders of eye care products.  Bristol-Myers 
Squibb developed a SCM system using the popular i2 SCM product line that offered clear 
benefits such as an optimized supply chain and reduced transportation costs.  Pfizer 
developed a Manugistics-based SCM system that consolidated inventory, logistics, and 
supply throughout the value chain.  Lastly, AstraZeneca also implemented an Extranet 
SCM solution using Manugistics for consolidating distribution, inventory, and modeling 
the supply chain.  Hence, a variety of software solutions were generally utilized in the 
pharmaceutical industry to develop eSupplyChain systems.   
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8.0. Chapter Eight:  Conclusion 
 It is time to reiterate the findings of this research, and analyze what eBusiness 
technologies and trends are being commonly pursued in a very diverse pharmaceutical 
industry.   
8.1. Pharmaceutical industry  
 
This is a very well-established industry with lots of potential of growth in the 
upcoming decades.  There are at least a dozen main players in this industry, many of 
which have been around for decades, some even centuriesJnJ, Merck, Pfizer, Novartis, 
GSK, Bayer, Bristol-Myers Squibb, Hoffman-LaRoche  to name a few.  These 
companies employ tens of thousands of employees worldwide, and many were originally 
founded in the 19th century by inventors, chemists, or doctors, who wanted to provide 
better medical products for humans.  These companies invest heavily in R&D and they 
are slowing moving to new technologies for implementing eBusiness solutions across 
their value chain.  R&D investments are in the millions and the revenues earned by these 
companies are in the billions.  Pharmaceutical companies mainly have divisions 
consisting of human, animal, and chemical products.  Finally, the drugs they produce are 
either prescription or OTC products. 
8.2. eBusiness 
 
There is no doubt that eBusiness will be an integral part of every pharmaceutical 
companys future strategies.  Many eBusiness phases and models are available to be 
pursued.  B2C is not as common in the pharmaceuticals, and it seems B2B is the most 
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widely used.  mBusiness is becoming popular in countries such as Japan.  C2C in terms 
of auctions is being used by pharmaceuticals for large events on websites like Free 
Markets Online, while some have implemented internal auctioning systems for suppliers 
and distributors. 
eBusiness technologies are all being effectively utilized in the pharmaceutical 
industry.  Web servers such as Microsoft IIS, Sun One Web Server, and BEA WebLogic 
are hosting numerous eBusiness websites for eSales an eMarketing and eDetailing.  
Partnerships have been formed with iPhysican.net for eDetailing.  Databases for many 
implementations include Oracle as the most common one.  Several firms have 
implemented middleware solutions with BEA Tuxedo and e.Piphany to integrate 
disparate distributed systems across global locations.   The most common application 
server being used is the J2EE based BEA WebLogic, followed by the SunOne and 
NetDynamics application servers.  Although open source application servers such as 
Jboss were mentioned in the eBusiness Infostructure section, none of the case studies 
actually revealed any pharmaceutical company deploying this product.   
The CRM market is begin dominated by Siebel, which has been replaced 
traditional manual and legacy systems with newly automated capabilities for forecasting, 
marketing, and sales.  ERP vendors have implemented their software in the 
pharmaceutical companies.  SAP is common for financials and human resources, 
followed by J.D. Edwards and PeopleSoft, which have also captured their fair share in the 
industry.  In terms of Procurement software, Ariba seems to be the most widely used.  
The SCM market is dominated by Manugistics and i2, while SAP is emerging as a 
contestant.   
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Emerging technologies such as Web Services were also mentioned in this 
research.  This technology was brought up in many interviews with executives in the 
pharmaceutical industry.  The common impression was that this technology does have 
value and prospects in the future, however, as we speak, not one of the companies was 
actually implementing them.  Similarly, open source Infostructure products such as Jboss 
or Apache Tomcat were not deployed in any production eBusiness applications in the 
pharmaceutical companies that were researched. 
8.3. eProcurement Analysis 
 
 Several eBusiness technologies have emerged in the eProcurement phase of 
pharmaceutical companies.  These products and vendors include:  
1. Ariba B2B eCommerce. 
2. SAP E-Procurement. 
 
These products have been successfully implemented in pharmaceutical companies such 
as Novartis, AstraZeneca, and other global companies.  These new eBusiness 
procurement systems replaced manual processes that consisted of handwritten, fax, or 
spreadsheets for previous implementations.  Both these companies develop a powerful 
suite of eBusiness products and remain the leaders in this market space.  
8.4. eSales Analysis 
 
Numerous eBusiness technologies have emerged in the eSales phase of the 
pharmaceutical companies.   
1. Database: Oracle. 
   119
2. J2EE Application Servers:  BEA WebLogic, SunOne Application Server, 
NetDynamics, and ATG Dynamo. 
3. Web Servers: BEA WebLogic and SunOne Web Server. 
4. CRM: Seibel Sales and Marketing. 
These products are being implemented in both custom and packaged eBusiness solutions.  
Most of the sales models being pursued are B2B, while there are some indications of 
mBusiness in Asia and some B2C in Asia and Europe.   
8.5. eSupplyChain Analysis 
 
 The eSupplyChain phase is being dominated by the two main players and one 
new entrant:  
1. i2 SCM. 
 
2. Manugistics SCM. 
 
3. mySAP SCM. 
 
All three of these packaged solutions for SCM are being implemented in the 
pharmaceutical industry.  Similar to eProcurement, these new systems have replaced 
traditionally manual or obsolete technologies.  These systems offer a new array of 
products that allow pharmaceutical companies to successfully monitor product 
throughout all phases of their value chain. 
It is clear that there are main players in the three eBusiness phases we discussed 
in this research.  SAP and Ariba dominate the procurement software; Sun, BEA, and 
Siebel seem to contend in the eSales solutions sector; finally, i2, Manugistics, and SAP 
are the contenders in developing SCM software.  Several companies have implemented 
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SCM systems that can be considered Extranet system of some sorts that are enabled using 
new package solutions such as Manugistics or other proprietary networks. 
In our quest to discover what is common in the pharmaceutical industry in terms 
of eBusiness, we have only discovered that this is a very diverse industry in terms of 
implementing eBusiness technologies and trends.  While some firms are implementing 
latest eBusiness technologies, others are still using EDI to perform B2B transactions for 
legacy backend systems.  This is a concerning thought, because EDI has been around for 
decades, and the fact that it works, does not necessarily mean it should be around forever.  
Hence, although pharmaceutical companies are on the right track with implementing 
eBusiness solutions across numerous phases of their value chain, obsolete technologies 
can still be found, not to mention those that have more recently replaced manual 
processes.  
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